

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines (Comirnaty [Pfizer-BioNTech] and Spikevax [Moderna]) administered to 12–17-year-olds in Victoria, Australia

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001472
Article Type:	Original research
Date Submitted by the Author:	08-Mar-2022
Complete List of Authors:	Cheng, Daryl; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Clothier, Hazel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Murdoch Children's Research Institute, Centre for Health Analytics Shenton, Priya; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Roney, Emma; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Murdoch Children's Research Institute, Centre for Health Analytics Cox, Nicholas; Western Health, Department of Cardiology Jones, Bryn; The Royal Children's Hospital Melbourne, Department of Cardiology Schrader, Silja; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Crawford, Nigel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Buttery, Jim; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne
Keywords:	COVID-19, Cardiology, Adolescent Health

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines (Comirnaty**
4 **[Pfizer-BioNTech] and Spikevax [Moderna]) administered to 12–17-year-olds in Victoria,**
5
6

7
8 **Australia**
9

10 **Authors:** Daryl R Cheng (0000-0001-5455-957X), Immunisation Consultant, SAEFVIC ^{1,2,3,4*},
11 Hazel J Clothier (0000-0001-7594-0361), Surveillance Manager, SAEFVIC ^{1,4,5*}, Priya Shenton,
12 immunisation fellow, SAEFVIC ¹, Emma Roney, Senior epidemiologist, SAEFVIC ^{1,4}, Nicholas
13 Cox (0000-0001-7442-2829), Director of Cardiology, Western Health ⁶, Bryn Jones, Deputy
14 Director of Cardiology, Royal Children's Hospital ^{2,3}, Silja Schrader (0000-0003-1776-6152),
15 data officer, SAEFVIC ¹, Nigel W Crawford (0000-0003-1851-5080), Director, SAEFVIC ^{1,2,3} **
16 and Jim P Buttery, Professor Child Health Informatics ^{1,2,3,4,**}, on behalf of the SAEFVIC and
17 VicSIS investigators
18
19
20

21 * Joint 1st authors

22 ** Joint senior authors
23
24

25 **Affiliations:**

26 ¹SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne,
27 Australia
28

29 ² The Royal Children's Hospital, Melbourne, Australia

30 ³ Department of Paediatrics, University of Melbourne, Melbourne, Australia,

31 ⁴ Centre for Health Analytics, Melbourne Children's Campus, Australia

32 ⁵ School of Population and Global Health, University of Melbourne, Parkville, Australia

33 ⁶ Department of Cardiology, Western Health, Sunshine, Australia
34
35

36 **Corresponding Author**

37 Daryl Cheng

38 SAEFVIC

39 50 Flemington Rd

40 Parkville

41 VIC 3052

42 E: daryl.cheng@mcri.edu.au
43
44
45

46 **Word Count:** 1457
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT**Importance:**

COVID-19 mRNA vaccine associated myocarditis has previously been described; however specific features in the paediatric / adolescent population are currently not well understood.

Objective

To describe myocarditis adverse events following immunization (AEFI) following any COVID-19 mRNA vaccines in the paediatric and adolescent population in Victoria, Australia.

Design

Statewide, population-based study.

Setting

Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) is the vaccine-safety service for Victoria, Australia.

Participants

All SAEFVIC reports of myocarditis and myopericarditis in 12–17-year-old COVID-19 mRNA vaccinees submitted between 22 February and 31 December 2021, as well as accompanying diagnostic investigation results where available, were assessed using Brighton Collaboration criteria for diagnostic certainty.

Exposures

Any mRNA COVID-19 vaccine

Main Outcomes/Measure

Confirmed myocarditis as per Brighton Collaboration criteria (levels 1-3)

Results

Rigorous clinical review demonstrated definite (Brighton level 1) or probable (level 2) diagnoses in 68 cases, with one case possible (level 3). The 69 reports of confirmed myocarditis equated to a rate of 8.5 per 100,000 doses in this age group. Cases were predominantly male (n=58, 84.1%) and post dose 2 (n=56, 81.2%). Rates peaked in the 16–17-year-old age group and were higher in males than females (14.1 v 2.8 per 100,000, $p < 0.001$).

Troponin levels differed between sexes, with males recording substantially higher levels.

Conclusion

Accurate evaluation and confirmation of episodes of COVID-19 mRNA vaccine associated myocarditis enabled understanding of clinical phenotypes in the paediatric and adolescent age group. Any potential vaccination and safety surveillance policies needs to consider age and gender differences.

What is already known on this topic

- Previous case studies suggest that there is an association between COVID-19 mRNA vaccines and increased rates of myocarditis
- Recommendations on use of COVID-19 mRNA vaccines in different age groups vary globally and may not take into account their different risk profiles.

What this study adds

- Incidence of myocarditis post COVID-19 mRNA vaccines are higher after the second dose and appears to differ by age and gender, with younger males being at a higher risk.
- Males with myocarditis have higher median troponin levels compared to females. Ongoing symptoms at one month post diagnosis were recorded in the majority of females, whereas the majority of males reported no ongoing symptoms at the same time point.

How this study might affect research, practice or policy

- Potential policy and safety surveillance adjustments may need to take into account age and gender differentials in myocarditis when reviewing COVID-19 vaccine rollout to the paediatric population

INTRODUCTION

Australia has utilized two mRNA vaccines as part of its COVID-19 vaccine strategy in 12-17 year-olds, namely Comirnaty BNT162b2 (BNT) COVID-19 (Pfizer-BioNTech) and Spikevax mRNA-1273 (Moderna).⁽¹⁾ Comirnaty was initially provisionally licensed by the Australian regulator, the Therapeutic Goods Administration (TGA) for those aged 16 years and older, and administered from 25 January 2021 in adults 18+ years. Spikevax received provisional TGA approval for administration in individuals from 18 years from 9 August 2021. Following the availability of age specific clinical trial data, further approvals were added for the 12–15-year-old group for Comirnaty (22nd July 2021) and 12–17-year-old for Spikevax (4th September 2021).

Of particular interest in the young adult population is post-vaccination myocarditis and pericarditis causally associated with COVID-19 mRNA vaccines. These adverse events of special interest (AESI) were first flagged in Israel, which implemented Comirnaty at a population level as soon as it was available (20th December 2020)⁽²⁾. In a linked electronic health record observational case control study design from Israel's largest health care insurer, Barda *et al* described an elevated risk of myocarditis following Comirnaty (risk ratio [RR], 3.24; 95% confidence interval [CI], 1.55 to 12.44) , while noting a substantially higher risk following COVID-19 disease (RR 18.28; 95% CI, 3.95 to 25.12).⁽³⁾

Subsequent post-licensure observational military and report-based case studies confirmed the highest risk group for post mRNA COVID-19 vaccine myocarditis is young males (<24 years old) following the 2nd vaccine dose ^(4, 5). Both the spontaneous (passive) Vaccine Adverse Event Reporting System and active Vaccine Safety Datalink surveillance systems in

1
2
3 the US have confirmed a myocarditis signal safety (6), along with similar findings in Canada,
4
5 the UK and various Nordic countries (7).
6
7
8
9

10 Due to this AESI signal, the risk, clinical manifestations and follow-up of myocarditis and
11 pericarditis following mRNA COVID-19 in younger populations has been of particular
12 interest. Some regions (e.g., Hong Kong) are only administering a single dose of mRNA
13 vaccine in adolescents aged 12-17 years and notably, there is limited use of Spikevax in this
14 age group internationally. Spikevax is not currently FDA licensed for 12-17 year-olds in the
15 United States, whilst Canada and several European countries have issued preferential
16 recommendations for Comirnaty over Spikevax for young adults (8). This study describes
17 clinical presentation and evaluation of myocarditis AESI following mRNA COVID-19
18 vaccination in 12–17-year-old adolescents in Victoria, Australia.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **METHODS**

36
37 Victoria is a south-eastern Australian state with a population of approximately 6.6 million
38 (9). AEFI are spontaneously reported by patients, caregivers or health-care providers to
39 SAEFVIC, the state-wide vaccine safety service(10). SAEFVIC comprises central reporting
40 enhanced passive and active surveillance systems integrated with clinical services that has
41 been operating since 2007.
42
43
44
45
46
47
48
49

50 Identified reports of myocarditis and myopericarditis in 12–17-year-old vaccinees submitted
51 to SAEFVIC between 22 February and 31 December 2021 were assessed. Myocarditis and
52 myopericarditis reports (henceforth summarized as myocarditis) were systematically
53 followed up and diagnostic test results (where available) obtained to confirm the diagnoses.
54
55
56
57
58
59
60

1
2
3 These included electrocardiogram (ECG), cardiac biomarkers, echocardiogram and cardiac
4
5 magnetic resonance imaging (MRI) scans. All troponin levels obtained were high sensitivity
6
7 troponin assays, with troponin levels reported as fold increase from the upper limit of
8
9 normal to facilitate comparison between different assays. Each case was categorized by at
10
11 least two independent experts utilizing the Brighton Collaboration definition with graded
12
13 levels of certainty.⁽¹¹⁾ All reports were forwarded to the national regulator, the Therapeutic
14
15 Goods Administration (TGA), who report weekly on spontaneous AEFI reports at a national
16
17 level ^(12, 13).

26 **Statistical analysis**

27
28 Data were analysed using Microsoft PowerBI (version 2.91.701.0) with 90% Poisson
29
30 confidence intervals calculated for rates. Vaccine doses administered and population
31
32 estimates were obtained from the Australian Immunisation Registry (AIR) (14). Age groups
33
34 were defined by the vaccine roll-out in Victoria, whereby 16–17-year-olds were eligible for
35
36 vaccination prior to 12–15-year-olds.

45 **RESULTS**

46
47 As of 31 December 2021, 488,570 12–17-year-old Victorians had received 807,490 mRNA
48
49 doses (722,849 Comirnaty and 84,641 Spikevax). This equated to approximately 84.3% first
50
51 dose and 81.1% of this age cohort fully vaccinated.

52
53 At this timepoint, there were 69 reports of confirmed myocarditis (43 myocarditis, 26
54
55 myopericarditis) as per Brighton Collaboration criteria level 1-3. 68 cases satisfied Brighton
56
57
58
59
60

1
2
3 Collaboration level 1 (definite) or 2 (probable) criteria, with one case level 3 (possible). This
4
5 equates to a rate of 8.5 per 100,000 doses (90% CI: 5.5, 8.7) in this age group (Table 1).
6
7

8
9 Cases were predominantly in males (n=58, 84.1%) and post dose 2 (n=56, 81.2%).
10

11 Presentation was temporally related to Comirnaty in 58 (84.1%) and to Spikevax in 11
12
13 (15.9%) cases respectively. Higher rates were observed in the 16–17-year-old age group,
14
15 and in males compared to females ($p<0.001$) (Table 1).
16
17

18
19 One patient had evidence of historical COVID-19 infection, with a positive COVID-19
20
21 respiratory PCR three weeks prior to receiving first dose Comirnaty vaccination – with
22
23 subsequent myocarditis two days later.
24
25

26
27 Onset of symptoms ranged from 0 to 49 days after vaccination, with a median of 2 days (IQR
28
29 1-3 days), in males from 0 to 34 days (median 2 days) and in females 1 to 49 days (median 3
30
31 days). Forty-seven cases (68.1%) required hospital admission with a median length of stay of
32
33 two nights. No cases required ICU admission and no deaths were recorded. All admissions
34
35 were discharged to home. Follow up at one month was completed for 62 cases (Table 2).
36
37

38
39 Symptoms had resolved in 40.3% of those who participated in follow-up, while 50.0%
40
41 remained on exercise restrictions.
42
43

44
45 ECG abnormalities were observed in 46 (66.7%) cases. An echocardiogram was performed in
46
47 66 cases and was abnormal in 8 (12.1%). A cardiac MRI was performed in 30 cases with
48
49 abnormalities documented in the majority of these (27 cases, 90.0%).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There was a clear differential in troponin levels between sexes, with males exhibiting higher
4
5 and more variable increases in troponin and a median fold rise of 138 times above normal
6
7 levels (Figure 1).
8
9

10 11 **DISCUSSION**

12
13
14
15 This study describes 69 cases of myocarditis reported following COVID-10 mRNA vaccination
16
17 in the adolescent age group. This equates to a rate of 8.5 cases per 100,000 doses (90% CI
18
19 6.9, 10.4).
20
21
22

23
24 This analysis describes one of the largest series of adolescents with myocarditis post-COVID-
25
26 19 mRNA vaccination to date. Rigorous clinical review of all cases demonstrated definite or
27
28 probable diagnoses in all but one case. This approach allows a more accurate evaluation of
29
30 clinical features and comparison with other presentations of non-COVID-19 mRNA vaccine
31
32 myocarditis or chest pain in this age group.
33
34
35

36
37 There were clear clinical phenotypic differences between sexes. Males tended to present
38
39 with symptoms in a tight window up to 7 days post dose 2 vaccine and with a significantly
40
41 elevated peak troponin level. Just under half had no residual symptoms 4 weeks after initial
42
43 onset. In contrast, females had a much lower median peak troponin level, with similar rates
44
45 post dose 1 and 2. Symptoms were still almost all female cases 4 weeks after onset. These
46
47 differences may support a potential impact of testosterone as a risk factor for stronger
48
49 cardiac inflammation in myocarditis, but with a potentially beneficial impact on duration of
50
51 symptoms. (15)
52
53
54
55
56
57
58
59
60

1
2
3 Our data indicates a higher rate of cases between the age of 16-17 and a tapering in rate for
4
5 the 12-15 age group. Further analysis is needed and ongoing to compare rates of
6
7 myocarditis between Comirnaty and Spikevax when sufficient doses are administered,
8
9 although there is currently no discernible difference in case severity or clinical presentation.
10
11
12

13
14 These observations suggest that any potential policy and safety surveillance adjustments
15
16 may need to take into account these age and gender differentials. For example, it has
17
18 implications for younger age groups, including those between 5-11 years, where a reduced
19
20 dose (10 mcg) Comirnaty vaccine was FDA approved and ACIP recommended in early
21
22 November 2021. (16) No COVID-19 vaccine clinical trials to date have been sufficiently
23
24 powered to detect an AESI such as myocarditis. However, with more than 7 million doses
25
26 administered in this age group at time of writing, real-world phase IV data will help inform
27
28 the important risk-benefit discussion regarding COVID-19 vaccines in younger children, who
29
30 from background rates of myocarditis (all causes) would be expected to have fewer cases
31
32 than adolescents.
33
34
35
36
37
38
39
40

41 **Limitations**

42
43 This study is based on clinical data compiled by SAEFVIC as part of vaccine safety
44
45 surveillance. A passive vaccine safety surveillance system may underreport potential cases
46
47 of myocarditis. Nonetheless, the accuracy of patient data was maintained by ensuring that
48
49 available patient clinical information were reviewed by at least two independent medical
50
51 specialists to verify reported myocarditis cases and reduce misdiagnosis.
52
53
54
55
56
57
58
59
60

Conclusion

Rates of myocarditis in the adolescent population differ by dose and sex in the 12- to 17-year-old. With the vaccine rollout in younger children and adolescents in mind, these clinical phenotypic differences, particularly between sexes, need to be considered for future COVID vaccine recommendations.

Acknowledgements:

SAEFVIC

Hannah Morgan, Greta Goldsmith, Samar Hikmat, Josh Osowicki, Linny Phuong, Mel Addison, Louise Dempsey, Adele Harris, Georgie Lewis, Bianca Penak, Laura Voss, Jaimee Craft, Victoria Scott, Lois Tham

Department of Health (Victoria)

Anna Power, Ngaree Blow, Elise Virah Sawmy, Eleanor Duckworth, Michelle Wolthuizen, Naveen Tenneti, Nick White, Melodie Heland, Sally Gordon

VicSIS paediatric clinic sites

Jane Standish (Barwon Health), Kathleen McCloskey (Barwon Health), Brooke Doherty (Barwon Health), Catie Fleming (Austin Health), Jeremy Carr (Monash Health), Matthew O'Brien (Monash Health), Paxton Loke (Monash Health), Ciara Earley (Monash Health), David Tran (Northern Health), Shane O'Dea (Northern Health), Lianne Cox (Western Health), Yoko Asakawa (Western Health), Teresa Lazzaro (RCH), Kirsten Perrett (RCH), Shidan Tosif

1
2
3 (RCH), Wonie Uahwatanasakul (RCH) and all other medical, nursing and administrative staff
4
5 that support the VicSIS clinics.
6
7
8
9

10 All other hospital sites and clinicians involved in providing information on cases.
11
12
13
14

15 **Footnotes**

16
17 Contributors: DC, NC, JB conceived and designed the study. HC and ER performed statistical
18
19 analyses and data management. All authors were involved in drafting, editing and reviewing
20
21 the article. All corresponding authors meet the authorship criteria. DC is the study's
22
23 guarantor.
24
25
26
27
28
29

30 Funding: This study was unfunded and was part of a routine clinical surveillance program.
31
32
33
34

35 Competing interests: All authors have completed the Unified Competing Interest
36
37 form (available on request from the corresponding author) and declare: no support from
38
39 any organisation for the submitted work; no financial relationships with any organisations
40
41 that might have an interest in the submitted work in the previous three years, no other
42
43 relationships or activities that could appear to have influenced the submitted work.
44
45
46
47
48
49

50 Ethics approval: Follow-up of cases was undertaken as part of public health AEFI
51
52 management. SAEFVIC data is part of a clinical quality registry that forms part of Victoria's
53
54 vaccine safety surveillance program.
55
56
57
58
59
60

1
2
3 Data sharing: Aggregated de-identified and summarized data is publicly available at
4
5 <https://mvec.mcri.edu.au/vaccinesafety/>
6
7
8
9

10 Patient Involvement: Patients were not involved in the report and conduct of this research,
11
12 as data was collected as part of public health AEFI management and was not a specific
13
14 research trial.
15
16
17
18
19

20 Transparency Declaration: The lead author, Dr Daryl Cheng, affirms that the manuscript is an
21
22 honest, accurate, and transparent account of the study being reported; that no important
23
24 aspects of the study have been omitted; and that any discrepancies from the study as
25
26 planned have been explained.
27
28
29

30
31
32 The Corresponding Author has the right to grant on behalf of all authors and does grant on
33
34 behalf of all authors, an exclusive licence (or non exclusive for government employees) on a
35
36 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
37
38 published in BMJ editions and any other BMJ PGL products and sublicences such use and
39
40 exploit all subsidiary rights, as set out in our licence.
41
42
43
44
45
46

47 **References**

- 48 1. Operation COVID Shield. National COVID Vaccine Campaign Plan. 2021.
- 49 2. Ministry of Health, Government of Israel. Surveillance of Myocarditis (Inflammation of
50 the Heart Muscle) Cases Between December 2020 and May 2021. 2021.
- 51 3. Barda N, Dagan N, Ben-Shlomo Y, *et al.* Safety of the BNT162b2 mRNA Covid-19
52 Vaccine in a Nationwide Setting. *New England Journal of Medicine*. 2021; doi:
53 10.1056/nejmoa2110475 [published Online.
- 54 4. Montgomery J, Ryan M, Engler R, *et al.* Myocarditis Following Immunization With
55 mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiology*.
56 2021;6:1202 doi: 10.1001/jamacardio.2021.2833 [published Online.
- 57
58
59
60


- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
5. Kim HW, Jenista ER, Wendell DC, *et al.* Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol.* 2021; doi: 10.1001/jamacardio.2021.2828 [published Online First: 2021/06/30].
 6. Centers for Disease Control and Prevention (CDC). ACIP Presentation Slides: November 2-3, 2021 Meeting. 2021.
 7. Patone M, Mei XW, Handunnetthi L, *et al.* Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nature Medicine.* 2021; doi: 10.1038/s41591-021-01630-0 [published Online.
 8. Gellad WF. Myocarditis after vaccination against covid-19. *Bmj.* 2021;**375**:n3090 doi: 10.1136/bmj.n3090 [published Online.
 9. Austalian Bureau of Statistics. National, state and territory population. 2020.
 10. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. *Commun Dis Intell Q Rep.* 2011;**35**:294-8 Online.
 11. Brighton Collaboration Myocarditis Working Group. Myocarditis/Pericarditis Case Definition. 2021.
 12. Therapeutic Goods Administration (TGA). Reporting suspected side effects associated with a COVID-19 vaccine. 2021; Online.
 13. Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report - 08-07-2021. 2021.
 14. Services Australia. Australian Immunisation Register. Australian Government 2021.
 15. Barcena ML, Jeuthe S, Niehues MH, *et al.* Sex-Specific Differences of the Inflammatory State in Experimental Autoimmune Myocarditis. *Frontiers in Immunology.* 2021;**12** doi: 10.3389/fimmu.2021.686384 [published Online.
 16. Centers for Disease Control and Prevention (CDC). COVID Data Tracker. 2021.

Table 1: Count and rate of cases by sex, age group, dose number, and Brighton Collaboration level

		Male		Female		Total	
		Count	Rate per 100,000 doses (90%CI)	Count	Rate per 100,000 doses (90%CI)	Count	Rate per 100,000 doses (90%CI)
Total		58	14.1 (11.2, 17.6)	11	2.8 (1.6, 4.6)	69	8.5 (6.9, 10.4)
Age group (years)	12-15	31	11.5 (8.3, 15.5)	6	2.3 (1.0, 4.5)	37	6.9 (5.2, 9.1)
	16-17	27	19.4 (13.7, 26.7)	5	3.7 (1.5, 7.8)	32	11.6 (8.5, 15.6)
Dose	1	10	4.8 (2.6, 8.1)	4	2.0 (0.7, 4.5)	14	3.4 (2.1, 5.3)
	2	49	24.4 (19.0, 31.0)	7	3.6 (1.7, 6.7)	56	14.2 (11.2, 17.7)
Brighton Collaboration level	1	23	5.6 (3.8, 7.9)	3	0.8 (0.2, 2.0)	26	3.2 (2.3, 4.5)
	2	34	8.3 (6.1, 11.0)	8	2.0 (1.0, 3.6)	42	5.2 (4.0, 6.7)
	3	1	0.2 (0.01, 1.2)	0	NA	1	0.1 (0.01, 0.6)

Table 2: One-month follow up outcomes, by sex (n=62)

	Male (n=53)	Female (n=9)	Total (n=62)
	Count, %	Count, %	Count, %
Symptoms resolved	24, 45.3%	1, 11.1%	25, 40.3%
On exercise restrictions	26, 49.1%	5, 55.6%	31, 50.0%



Scale on x axis has been truncated for ease of interpretation. Male dose 2 extends to 2909.09

413x119mm (38 x 38 DPI)

BMJ Paediatrics Open

Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12–17-year-olds in Victoria, Australia

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001472.R1
Article Type:	Original research
Date Submitted by the Author:	25-Apr-2022
Complete List of Authors:	Cheng, Daryl; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Clothier, Hazel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Campus, Centre for Health Analytics Morgan, Hannah; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Campus, Centre for Health Analytics Roney, Emma; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Centre, Centre for Health Analytics Shenton, Priya; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Cox, Nicholas; Western Health, Department of Cardiology Jones, Bryn; The Royal Children's Hospital Melbourne, Department of Cardiology Schrader, Silja; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Crawford, Nigel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Buttery, Jim; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne
Keywords:	COVID-19, Cardiology, Adolescent Health

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to**
4
5
6 **12–17-year-olds in Victoria, Australia**
7

8 **Authors:** Daryl R Cheng (0000-0001-5455-957X), Immunisation Consultant, SAEFVIC ^{1,2,3,4*},
9 Hazel J Clothier (0000-0001-7594-0361), Surveillance Manager, SAEFVIC ^{1,4,5*}, Priya Shenton,
10 immunisation fellow, SAEFVIC ¹, Emma Roney, Senior epidemiologist, SAEFVIC ^{1,4}, Hannah
11 Morgan, Senior epidemiologist, SAEFVIC ^{1,3,4}, Nicholas Cox (0000-0001-7442-2829), Director
12 of Cardiology, Western Health ⁶, Bryn Jones, Deputy Director of Cardiology, Royal Children's
13 Hospital ^{2,3}, Silja Schrader (0000-0003-1776-6152), data officer, SAEFVIC ¹, Nigel W Crawford
14 (0000-0003-1851-5080), Director, SAEFVIC ^{1,2,3} ** and Jim P Buttery, Professor Child Health
15 Informatics ^{1,2,3,4,**}, on behalf of the SAEFVIC and VicSIS investigators
16
17

18
19 * Joint 1st authors

20 ** Joint senior authors
21

22
23 **Affiliations:**

24 ¹SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne,
25 Australia

26 ² The Royal Children's Hospital, Melbourne, Australia

27 ³ Department of Paediatrics, University of Melbourne, Melbourne, Australia,

28 ⁴ Centre for Health Analytics, Melbourne Children's Campus, Australia

29 ⁵ Melbourne School of Population and Global Health, University of Melbourne, Parkville,
30 Australia

31 ⁶ Department of Cardiology, Western Health, Sunshine, Australia
32
33

34
35 **Corresponding Author**

36 Daryl Cheng

37 SAEFVIC

38 50 Flemington Rd

39 Parkville

40 VIC 3052

41 E: daryl.cheng@rch.org.au
42
43

44 **Word Count:** 1457
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Importance:

COVID-19 mRNA vaccine associated myocarditis has previously been described; however specific features in the adolescent population are currently not well understood.

Objective

To describe myocarditis adverse events following immunization (AEFI) reported following any COVID-19 mRNA vaccines in the paediatric and adolescent population in Victoria, Australia.

Design

Statewide, population-based study.

Setting

Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) is the vaccine-safety service for Victoria, Australia.

Participants

All SAEFVIC reports of myocarditis and myopericarditis in 12–17-year-old COVID-19 mRNA vaccinees submitted between 22 February 2021 and 22 February 2022, as well as accompanying diagnostic investigation results where available, were assessed using Brighton Collaboration criteria for diagnostic certainty.

Exposures

Any mRNA COVID-19 vaccine

Main Outcomes/Measure

Confirmed myocarditis as per Brighton Collaboration criteria (levels 1-2)

Results

Rigorous clinical review demonstrated definite (Brighton level 1) or probable (level 2) diagnoses in 75 cases. Confirmed myocarditis reporting rates were 8.3 per 100,000 doses in this age group. Cases were predominantly male (n=62, 82.7%) and post dose 2 (n=61, 81.3%). Rates peaked in the 16–17-year-old age group and were higher in males than females (17.7 v 3.9 per 100,000, $p < 0.001$).

Troponin levels differed between sexes, with males recording substantially higher levels.

Conclusion

Accurate evaluation and confirmation of episodes of COVID-19 mRNA vaccine associated myocarditis enabled understanding of clinical phenotypes in the adolescent age group. Any potential immunisation safety policies need to take into account age and gender differences.

What is already known on this topic

- Previous studies support an association between COVID-19 mRNA vaccine receipt and increased rates of myocarditis in the following 2 weeks
- Recommendations on use of COVID-19 mRNA vaccines in different age groups vary globally and may not take into account their different risk profiles.

What this study adds

- Incidence of myocarditis post COVID-19 mRNA vaccines are higher after the second dose and appears to differ by age and gender, with adolescent and young adult males being at a higher risk.
- The clinical phenotype of myocarditis differs between genders in adolescents, with females recording lower median troponin levels but longer lasting clinical symptoms

How this study might affect research, practice or policy

- Potential policy and safety surveillance adjustments may need to take into account age and gender differentials in myocarditis when reviewing the COVID-19 primary (2-dose) vaccine rollout to the paediatric population

INTRODUCTION

Australia has utilized two mRNA vaccines as part of its COVID-19 vaccine strategy in 12-17 year-olds, namely Comirnaty® BNT162b2 COVID-19 (Pfizer-BioNTech) and Spikevax® mRNA-1273 (Moderna). (1) Comirnaty was initially provisionally licensed by the Australian regulator, the Therapeutic Goods Administration (TGA) for those aged 16 years and older, and administered from 25 January 2021 in adults 18+ years. Spikevax received provisional TGA approval for administration in individuals from 18 years from 9 August 2021. Following the availability of age specific clinical trial data, further approvals were added for the 12–15-year-old group for Comirnaty (22nd July 2021) and 12–17-year-old for Spikevax (4th September 2021).

Of particular interest in the young adult population is post-vaccination myocarditis and pericarditis causally associated with COVID-19 mRNA vaccines. These adverse events of special interest (AESI) were first flagged in Israel, which implemented Comirnaty at a population level as soon as it was available (20th December 2020). (2) In a linked electronic health record observational case control study design from Israel's largest health care insurer, Barda *et al* described an elevated risk of myocarditis following Comirnaty (risk ratio [RR], 3.24; 95% confidence interval [CI], 1.55, 12.44), while noting a substantially higher risk following COVID-19 disease (RR 18.28; 95% CI, 3.95, 25.12). (3)

Subsequent post-licensure observational military and report-based case studies confirmed the highest risk group for post mRNA COVID-19 vaccine myocarditis is young males (<24 years old) following the 2nd vaccine dose. (4-6) Both the spontaneous Vaccine Adverse Event Reporting System and active Vaccine Safety Datalink surveillance systems in the US have

1
2
3 confirmed a myocarditis signal safety (7), along with similar findings in Canada, the UK and
4
5 various Nordic countries. (6)
6
7
8
9

10 Due to this AESI signal, the risk, clinical manifestations and follow-up of myocarditis and
11
12 pericarditis following mRNA COVID-19 in younger populations has been of particular
13
14 interest. Some regions (e.g., Hong Kong) are only administering a single dose of mRNA
15
16 vaccine in adolescents aged 12-17 years and notably, there is limited use of Spikevax in this
17
18 age group internationally. Spikevax is not currently licensed by the US Food and Drug
19
20 Administration (FDA) for 12-17 year-olds, whilst Canada and several European countries
21
22 have issued preferential recommendations for Comirnaty over Spikevax for young adults. (8)
23
24
25 This study describes clinical presentation and evaluation of myocarditis AESI following
26
27 mRNA COVID-19 vaccination in 12–17-year-old adolescents in Victoria, Australia.
28
29
30
31
32
33
34

35 **METHODS**

36
37 Victoria is a south-eastern Australian state with a population of approximately 6.6 million.
38
39 (9) AEFI are spontaneously reported by patients, caregivers or health-care providers to
40
41 SAEFVIC, the state-wide vaccine safety service. (10) SAEFVIC comprises central reporting
42
43 enhanced passive and active surveillance systems integrated with clinical services that has
44
45 been operating since 2007.
46
47
48
49

50 Identified reports of myocarditis and myopericarditis in 12–17-year-old vaccinees submitted
51
52 to SAEFVIC between 22 February 2021 and 22 February 2022 were assessed. The majority of
53
54 these were practitioner reported. Myocarditis and myopericarditis reports (henceforth
55
56 summarized as myocarditis) were systematically followed up and diagnostic test results
57
58
59
60

1
2
3 (where available) obtained to confirm the diagnoses, including potential alternative causes
4
5 such as viral, autoimmune or medication related myocarditis. Data gathered included
6
7 symptoms such as chest pain, shortness of breath, dizziness and fatigue, as well as
8
9 investigations undertaken by treating clinicians, including electrocardiogram (ECG), cardiac
10
11 biomarkers, echocardiogram and cardiac magnetic resonance imaging (MRI) scans. All
12
13 troponin levels obtained were high sensitivity troponin assays, with troponin levels reported
14
15 as fold increase from the upper limit of normal to facilitate comparison between different
16
17 assays.
18
19
20
21
22
23

24 Each case was categorized by at least two independent experts utilizing the Brighton
25
26 Collaboration definition with graded levels of certainty. (11) All reports were forwarded to
27
28 the Australian national regulator, the Therapeutic Goods Administration (TGA), who report
29
30 weekly on spontaneous AEFI reports at a national level. (12, 13)
31
32
33

34 Cases where vaccination was the most likely cause of their diagnosis were followed up after
35
36 1 month to answer a series of questions about ongoing symptoms and clinical management.
37
38 Cases were declared lost to follow up after 3 calls.
39
40
41
42

43 **Statistical analysis**

44
45 Data were analysed using Microsoft PowerBI (version 2.91.701.0) with 90% Poisson
46
47 confidence intervals calculated for rates. Vaccine doses administered and population
48
49 estimates were obtained from the Australian Immunisation Registry (AIR). (14) Age groups
50
51 were defined by the vaccine roll-out in Victoria, whereby 16–17-year-olds were eligible for
52
53 vaccination prior to 12–15-year-olds.
54
55
56
57
58
59
60

RESULTS

As of 22 February 2022, 454,974 12–17-year-old Victorians had received 871,689 mRNA doses (782,964 Comirnaty and 88,725 Spikevax). This equated to approximately 97.9% first dose and 93.7% 2nd dose coverage of this age cohort.

At this timepoint, there were 75 reports of confirmed myocarditis (45 myocarditis, 31 myopericarditis) as per Brighton Collaboration level 1 (definite) or 2 (probable) criteria. This equates to a rate of 8.3 per 100,000 doses (90% CI: 6.8, 10.1) in this age group (Table 1).

Cases were predominantly in males (n=62, 82.7%) and post dose 2 (n=61, 81.3%).

Presentation was temporally related to Comirnaty in 63 (84.0%) and to Spikevax in 12 (16.0%) cases respectively. Higher rates were observed in the 16–17-year-old age group, and in males compared to females (p<0.001) (Table 1).

Of the 75 cases in the study period, 5 of them were found to have a cause for myocarditis that was considered more likely by treating clinicians than COVID-19 vaccination. One patient had evidence of historical COVID-19 infection, with a positive COVID-19 respiratory PCR three weeks prior to receiving first dose Comirnaty vaccination – with subsequent myocarditis two days later.

For the 70 cases related to COVID-10 mRNA vaccination, onset of symptoms ranged from 0 to 49 days after vaccination, with a median of 2 days (IQR 1-3 days), in males from 0 to 34 days (median 2 days) and in females 1 to 49 days (median 2 days). Fifty-one cases (68.0%) required hospital admission with a median length of stay of two nights. No cases required ICU admission and no deaths were recorded. All admissions were discharged to home.

1
2
3 ECG abnormalities were observed in 51 (68.0%) cases. An echocardiogram was performed in
4
5 70 cases and was abnormal in 8 (11.4%). An initial diagnostic cardiac MRI was performed in
6
7 35 cases with abnormalities documented in the majority of these (31 cases, 88.6%).
8
9

10
11 There was a clear differential in troponin levels between sexes, with males exhibiting higher
12
13 and more variable increases in troponin and a median fold rise of 144 times above normal
14
15 levels (Figure 1).
16
17
18

19
20 Follow up at one month was completed for 64 of the 70 cases where COVID-19 vaccination
21
22 was the most likely cause of their diagnosis (Table 2). The remaining 6 cases were lost to
23
24 follow-up and excluded from analysis. Symptoms had resolved in 50.0% while 64.1%
25
26 remained on exercise restrictions.
27
28
29

30 31 **DISCUSSION** 32

33
34 We describe 75 cases of myocarditis reported following COVID-10 mRNA vaccination in the
35
36 adolescent age group. This equates to a rate of 8.3 cases per 100,000 doses (90% CI: 6.8,
37
38 10.1). This rate is similar to other international studies in Israel, the UK and the USA. (13)
39
40
41

42
43 This analysis describes one of the largest series of adolescents with myocarditis post-COVID-
44
45 19 mRNA vaccination to date. Rigorous clinical review of all cases demonstrated definite or
46
47 probable diagnoses (as per Brighton criteria). This approach allows a more accurate
48
49 evaluation of clinical features and comparison with other presentations of non-COVID-19
50
51 mRNA vaccine myocarditis or chest pain in this age group.
52
53

54
55 Findings were similar to other international cohorts of adolescents. Dionne *et al* described
56
57 similar symptom prevalence in a cohort of myocarditis patients <19 years. (15) There was
58
59
60

1
2
3 also similar cardiac MRI abnormalities noted in similar cohorts. (16) In contrast to our
4 findings, the cohort from Truong *et al* had a high number of patients (18.7%) requiring ICU
5 admission, although only 2 required inotropic support. (17) It is likely that the difference in
6 ICU admission criteria, rather than true clinical severity accounts for this discrepancy.
7
8
9
10
11

12
13
14 Unique to this study is the clear clinical phenotypic differences identified between sexes.

15
16 Males tended to present with symptoms in a tight window up to 7 days post dose 2 vaccine
17 and with a significantly elevated peak troponin level. Just under half had no residual
18 symptoms 4 weeks after initial onset. In contrast, females had a much lower median peak
19 troponin level, with similar rates post dose 1 and 2. Symptoms were still experienced in the
20 majority of female cases 4 weeks after onset. These differences may support a potential
21 impact of testosterone as a risk factor for stronger cardiac inflammation in myocarditis, but
22 with a potentially beneficial impact on duration of symptoms. (18)
23
24
25
26
27
28
29
30
31
32

33
34
35 Our data indicates a higher rate of cases between the age of 16-17 years and a tapering in
36 rate for the 12-15 year old age group. Further analysis is needed and ongoing to compare
37 rates of myocarditis between Comirnaty and Spikevax when sufficient doses are
38 administered, although there is currently no discernible difference in case severity or clinical
39 presentation.
40
41
42
43
44
45
46
47

48 These observations suggest that any potential immunisation policy and vaccine safety
49 surveillance adjustments may need to take into account these age and gender differentials.
50

51 For example, it has implications for younger age groups, including those between 5-11
52 years, where a reduced dose (10 mcg) Comirnaty vaccine was FDA approved and Advisory
53 Committee on Immunization Practices (ACIP) recommended in early November 2021. (19)
54
55
56
57
58
59
60

1
2
3 No COVID-19 vaccine clinical trials to date have been sufficiently powered to detect an AESI
4 such as myocarditis. However, with millions of doses administered worldwide in this age
5
6 group at time of writing, real-world phase IV data will help inform the important risk-benefit
7
8 discussion regarding COVID-19 vaccines in younger children, who from background rates of
9
10 myocarditis (all causes) would be expected to have fewer cases than adolescents.
11
12
13
14
15
16
17

18 **LIMITATIONS**

19
20 This study is based on clinical data compiled by SAEFVIC as part of vaccine safety
21
22 surveillance. A passive vaccine safety surveillance system may underreport potential cases
23
24 of myocarditis. Furthermore, there was lack of clinical data on some cases (eg.
25
26 investigations not performed), making evaluation and diagnosis more challenging. Whilst
27
28 patient reported symptoms were included as part of the evaluation, Brighton diagnostic
29
30 criteria was used as a benchmark to reduce recall bias. The accuracy of diagnosis was also
31
32 maintained by ensuring that available patient clinical information were reviewed by at least
33
34 two independent medical specialists to verify reported myocarditis cases and reduce
35
36 misdiagnosis.
37
38
39
40
41
42
43
44

45 **CONCLUSION**

46
47 Rates of myocarditis in the adolescent population differ by dose and sex in the 12 to 17
48
49 year-old age-group. With the vaccine rollout in younger children and adolescents in mind,
50
51 these clinical phenotypic differences, should be considered for future COVID vaccine
52
53 recommendations, including 'booster' doses.
54
55
56
57
58
59
60

Acknowledgements:**SAEFVIC**

Greta Goldsmith, Samar Hikmat, Josh Osowicki, Linny Phuong, Mel Addison, Louise Dempsey, Adele Harris, Georgie Lewis, Bianca Penak, Laura Voss, Jaimee Craft, Victoria Scott, Lois Tham

Department of Health (Victoria)

Anna Power, Ngaree Blow, Elise Virah Sawmy, Eleanor Duckworth, Michelle Wolthuizen, Naveen Tenneti, Nick White, Melodie Heland, Sally Gordon

VicSIS paediatric clinic sites

Jane Standish (Barwon Health), Kathleen McCloskey (Barwon Health), Brooke Doherty (Barwon Health), Catie Fleming (Austin Health), Jeremy Carr (Monash Health), Matthew O'Brien (Monash Health), Paxton Loke (Monash Health), Ciara Earley (Monash Health), David Tran (Northern Health), Shane O'Dea (Northern Health), Lianne Cox (Western Health), Yoko Asakawa (Western Health), Teresa Lazzaro (RCH), Kirsten Perrett (RCH), Shidan Tosif (RCH), Wonie Uahwatanasakul (RCH) and all other medical, nursing and administrative staff that support the VicSIS clinics.

All other hospital sites and clinicians involved in providing information on cases.

Footnotes

Contributors: DC, NC, JB conceived and designed the study. HC, ER and HM performed statistical analyses and data management. All authors were involved in drafting, editing and reviewing the article. All corresponding authors meet the authorship criteria. DC is the study's guarantor.

Funding: This study was unfunded and was part of a routine clinical surveillance program.

Competing interests: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval: Follow-up of cases was undertaken as part of public health AEFI management. SAEFVIC data is part of a clinical quality registry that forms part of Victoria's vaccine safety surveillance program.

Data sharing: Aggregated de-identified and summarized data is publicly available at <https://mvec.mcri.edu.au/vaccinesafety/>

Patient Involvement: Patients were not involved in the report and conduct of this research, as data was collected as part of public health AEFI management and was not a specific research trial.

1
2
3 Transparency Declaration: The lead author, Dr Daryl Cheng, affirms that the manuscript is an
4 honest, accurate, and transparent account of the study being reported; that no important
5 aspects of the study have been omitted; and that any discrepancies from the study as
6 planned have been explained.
7
8
9
10
11
12
13
14

15 The Corresponding Author has the right to grant on behalf of all authors and does grant on
16 behalf of all authors, an exclusive licence (or non exclusive for government employees) on a
17 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
18 published in BMJ editions and any other BMJ PGL products and sublicences such use and
19 exploit all subsidiary rights, as set out in our licence.
20
21
22
23
24
25
26
27
28
29

30 References

- 31 1. Operation COVID Shield. National COVID Vaccine Campaign Plan. 2021.
- 32 2. Ministry of Health, Government of Israel. Surveillance of Myocarditis (Inflammation of the
33 Heart Muscle) Cases Between December 2020 and May 2021. 2021.
- 34 3. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a
35 Nationwide Setting. *New England Journal of Medicine*. 2021; doi: 10.1056/nejmoa2110475
36 [published Online].
- 37 4. Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA
38 COVID-19 Vaccines in Members of the US Military. *JAMA Cardiology*. 2021;6:1202 doi:
39 10.1001/jamacardio.2021.2833 [published Online].
- 40 5. Kim HW, Jenista ER, Wendell DC, et al. Patients With Acute Myocarditis Following mRNA
41 COVID-19 Vaccination. *JAMA Cardiol*. 2021; doi: 10.1001/jamacardio.2021.2828 [published
42 Online First: 2021/06/30].
- 43 6. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac
44 arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nature
45 Medicine*. 2021; doi: 10.1038/s41591-021-01630-0 [published Online].
- 46 7. Centers for Disease Control and Prevention. ACIP Presentation Slides: November 2-3, 2021
47 Meeting. 2021.
- 48 8. Gellad WF. Myocarditis after vaccination against covid-19. *Bmj*. 2021;375:n3090 doi:
49 10.1136/bmj.n3090 [published Online].
- 50 9. Australian Bureau of Statistics. National, state and territory population. 2020.
- 51 10. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following
52 immunisation: the model of SAEFVIC, Victoria. *Commun Dis Intell Q Rep*. 2011;35:294-8
53 Online.
- 54 11. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, et al. Myocarditis and pericarditis: Case
55 definition and guidelines for data collection, analysis, and presentation of immunization
56
57
58
59
60

- 1
2
3 safety data. *Vaccine*. 2022;40:1499-511 doi: 10.1016/j.vaccine.2021.11.074 [published
4 Online First: 2022/02/03].
- 5 12. Therapeutic Goods Administration (TGA). Reporting suspected side effects associated with a
6 COVID-19 vaccine. 2021; Online.
- 7 13. Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report -
8 14.04.2022. 2022.
- 9 14. Services Australia. Australian Immunisation Register. Australian Government 2021.
- 10 15. Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2
11 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiol*. 2021;6:1446-
12 50 doi: 10.1001/jamacardio.2021.3471 [published Online First: 2021/08/11].
- 13 16. Jain SS, Steele JM, Fonseca B, et al. COVID-19 Vaccination-Associated Myocarditis in
14 Adolescents. *Pediatrics*. 2021;148 doi: 10.1542/peds.2021-053427 [published Online First:
15 2021/08/15].
- 16 17. Truong DT, Dionne A, Muniz JC, et al. Clinically Suspected Myocarditis Temporally Related to
17 COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-
18 19 Vaccination. *Circulation*. 2022;145:345-56 doi: 10.1161/circulationaha.121.056583
19 [published Online First: 2021/12/07].
- 20 21 18. Barcena ML, Jeuthe S, Niehues MH, et al. Sex-Specific Differences of the Inflammatory State
22 in Experimental Autoimmune Myocarditis. *Frontiers in Immunology*. 2021;12 doi:
23 10.3389/fimmu.2021.686384 [published Online].
- 24 25 19. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US
26 Department of Health and Human Services, CDC; 2022, Accessed April 14. Available from:
27 <https://covid.cdc.gov/covid-data-tracker>
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Table 1: Count and rate of cases by sex, age group, dose number, and Brighton Collaboration level

		Male		Female		Total	
		Count	Rate per 100,000 doses (90%CI)	Count	Rate per 100,000 doses (90%CI)	Count	Rate per 100,000 doses (90%CI)
Total		62	13.6 (10.9, 16.8)	13	2.9 (1.7, 4.7)	75	8.3 (6.8, 10.1)
Age group (years)	12-15	34	11.4 (8.4, 15.2)	7	2.4 (1.1, 4.6)	41	7.0 (5.3, 9.1)
	16-17	28	17.7 (12.6, 24.2)	6	3.9 (1.7, 7.6)	34	10.8 (8.0, 14.4)
Dose	1	10	4.4 (2.4, 7.5)	4	1.8 (0.6, 4.2)	14	3.2 (1.9, 4.9)
	2	52	24.2 (19.0, 30.5)	9	4.3 (2.3, 7.5)	61	14.4 (11.5, 17.8)
Brighton Collaboration level	1	27	5.9 (4.2, 8.2)	3	0.7 (0.2, 1.8)	30	3.3 (2.4, 4.5)
	2	35	7.7 (5.7, 10.2)	10	2.3 (1.2, 3.8)	45	5.0 (3.8, 6.4)

	Male (n=56)	Female (n=8)	Total (n=64)	Chi-square statistic (p-value)
	Count, %	Count, %	Count, %	
Symptoms resolved	31, 55.4%	1, 12.5%	32, 50.0%	5.14 (p=0.02)
On exercise restrictions	35, 62.5%	6, 75.0%	41, 64.1%	0.48 (p=0.49)

Table 2: One-month follow up outcomes, by sex (n=64)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



327x93mm (96 x 96 DPI)

BMJ Paediatrics Open

Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12–17-year-olds in Victoria, Australia

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001472.R2
Article Type:	Original research
Date Submitted by the Author:	05-May-2022
Complete List of Authors:	Cheng, Daryl; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Clothier, Hazel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Campus, Centre for Health Analytics Morgan, Hannah; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Campus, Centre for Health Analytics Roney, Emma; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Centre, Centre for Health Analytics Shenton, Priya; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Cox, Nicholas; Western Health, Department of Cardiology Jones, Bryn; The Royal Children's Hospital Melbourne, Department of Cardiology Schrader, Silja; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Crawford, Nigel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Buttery, Jim; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne
Keywords:	COVID-19, Cardiology, Adolescent Health

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to**
4
5
6 **12–17 year-olds in Victoria, Australia**
7

8 **Authors:** Daryl R Cheng (0000-0001-5455-957X), Immunisation Consultant, SAEFVIC ^{1,2,3,4*},
9 Hazel J Clothier (0000-0001-7594-0361), Principal epidemiologist and Surveillance Manager,
10 SAEFVIC ^{1,4,5*}, Priya Shenton, immunisation fellow, SAEFVIC ¹, Emma Roney, Senior
11 epidemiologist, SAEFVIC ^{1,4}, Hannah Morgan, Senior epidemiologist, SAEFVIC ^{1,3,4}, Nicholas
12 Cox (0000-0001-7442-2829), Director of Cardiology, Western Health ⁶, Bryn Jones, Deputy
13 Director of Cardiology, Royal Children's Hospital ^{2,3}, Silja Schrader (0000-0003-1776-6152),
14 data officer, SAEFVIC ¹, Nigel W Crawford (0000-0003-1851-5080), Director, SAEFVIC ^{1,2,3} **
15 and Jim P Buttery, Professor Child Health Informatics ^{1,2,3,4,**}, on behalf of the SAEFVIC and
16 VicSIS investigators
17
18
19

20 * Joint 1st authors

21 ** Joint senior authors
22
23

24 **Affiliations:**

25 ¹SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne,
26 Australia

27 ² The Royal Children's Hospital, Melbourne, Australia

28 ³ Department of Paediatrics, University of Melbourne, Melbourne, Australia,

29 ⁴ Centre for Health Analytics, Melbourne Children's Campus, Australia

30 ⁵ Melbourne School of Population and Global Health, University of Melbourne, Parkville,
31 Australia

32 ⁶ Department of Cardiology, Western Health, Sunshine, Australia
33
34
35

36 **Corresponding Author**

37 Daryl Cheng

38 SAEFVIC

39 50 Flemington Rd

40 Parkville

41 VIC 3052

42 E: daryl.cheng@mcri.edu.au
43
44
45

46 **Word Count:** 1768
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT**Importance:**

COVID-19 mRNA vaccine associated myocarditis has previously been described; however specific features in the adolescent population are currently not well understood.

Objective

To describe myocarditis adverse events following immunization (AEFI) reported following any COVID-19 mRNA vaccines in the adolescent population in Victoria, Australia.

Design

Statewide, population-based study.

Setting

Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) is the vaccine-safety service for Victoria, Australia.

Participants

All SAEFVIC reports of myocarditis and myopericarditis in 12–17-year-old COVID-19 mRNA vaccinees submitted between 22 February and 22 February 2021, as well as accompanying diagnostic investigation results where available, were assessed using Brighton Collaboration criteria for diagnostic certainty.

Exposures

Any mRNA COVID-19 vaccine

Main Outcomes/Measure

Confirmed myocarditis as per Brighton Collaboration criteria (levels 1-3)

Results

Clinical review demonstrated definitive (Brighton level 1) or probable (level 2) diagnoses in 75 cases. Confirmed myocarditis reporting rates were 8.3 per 100,000 doses in this age group. Cases were predominantly male (n=62, 82.7%) and post dose 2 (n=61, 81.3%). Rates peaked in the 16–17year-old age group and were higher in males than females (17.7 v 3.9 per 100,000, $p<0.001$).

Troponin levels differed between sexes, with males recording higher levels ($p=0.222$).

Conclusion

Accurate evaluation and confirmation of episodes of COVID-19 mRNA vaccine associated myocarditis enabled understanding of clinical phenotypes in the adolescent age group. Any potential vaccination and safety surveillance policies needs to consider age and gender differences.

What is already known on this topic

- Previous case studies suggest that there is an association between COVID-19 mRNA vaccines and increased rates of myocarditis, most commonly in the following 2 weeks
- Recommendations on use of COVID-19 mRNA vaccines in different age groups vary globally and may not take into account their different risk profiles.

What this study adds

- Incidence of myocarditis post COVID-19 mRNA vaccines are higher after the second dose and appears to differ by age and gender, with adolescent and young adult males being at a higher risk.
- The clinical phenotype of myocarditis differs between genders in adolescents, with females recording lower median troponin levels but longer lasting clinical symptoms

How this study might affect research, practice or policy

- Potential policy and safety surveillance adjustments may need to take into account age and gender differentials in myocarditis when reviewing COVID-19 primary (2-dose) vaccine rollout to the adolescent population

INTRODUCTION

Australia has utilized two mRNA vaccines as part of its COVID-19 vaccine strategy in 12-17 year-olds, namely Comirnaty® BNT162b2 COVID-19 (Pfizer-BioNTech) and Spikevax® mRNA-1273 (Moderna).⁽¹⁾ Comirnaty was initially provisionally licensed by the Australian regulator, the Therapeutic Goods Administration (TGA) for those aged 16 years and older, and administered from 25 January 2021 in adults 18+ years. Spikevax received provisional TGA approval for administration in individuals from 18 years from 9 August 2021. Following the availability of age specific clinical trial data, further approvals were added for the 12–15-year-old group for Comirnaty (22nd July 2021) and 12–17-year-old for Spikevax (4th September 2021).

Of particular interest in the young adult population is post-vaccination myocarditis and pericarditis causally associated with COVID-19 mRNA vaccines. These adverse events of special interest (AESI) were first flagged in Israel, which implemented Comirnaty at a population level as soon as it was available (20th December 2020)⁽²⁾. In a linked electronic health record observational case control study design from Israel's largest health care insurer, Barda *et al* described an elevated risk of myocarditis following Comirnaty (risk ratio [RR], 3.24; 95% confidence interval [CI], 1.55 to 12.44) , while noting a substantially higher risk following COVID-19 disease (RR 18.28; 95% CI, 3.95 to 25.12).⁽³⁾

Subsequent post-licensure observational military and report-based case studies confirmed the highest risk group for post mRNA COVID-19 vaccine myocarditis is young males (<24 years old) following the 2nd vaccine dose ⁽⁴⁻⁶⁾. Both the spontaneous Vaccine Adverse Event Reporting System and active Vaccine Safety Datalink surveillance systems in the US have

1
2
3 confirmed a myocarditis signal safety (7), along with similar findings in Canada, the UK and
4
5 various Nordic countries (6).
6
7
8
9

10 Due to this AESI signal, the risk, clinical manifestations and follow-up of myocarditis and
11 pericarditis following mRNA COVID-19 in younger populations has been of particular
12
13 interest. Some regions (e.g., Hong Kong) are only administering a single dose of mRNA
14
15 vaccine in adolescents aged 12-17 years and notably, there is limited use of Spikevax in this
16
17 age group internationally. Spikevax is not currently licensed by the US Food and Drug
18
19 Administration (FDA) for 12-17 year-olds, whilst Canada and several European countries
20
21 have issued preferential recommendations for Comirnaty over Spikevax for young adults. (8)
22
23 This study describes clinical presentation and evaluation of myocarditis AESI following
24
25 mRNA COVID-19 vaccination in 12–17-year-old adolescents in Victoria, Australia.
26
27
28
29
30
31
32
33
34

35 **METHODS**

36
37 Victoria is a south-eastern Australian state with a population of approximately 6.6 million.
38
39 (9) AEFI are spontaneously reported by patients, caregivers or health-care providers to
40
41 SAEFVIC, the state-wide vaccine safety service. (10) SAEFVIC comprises central reporting
42
43 enhanced passive and active surveillance systems integrated with clinical services and has
44
45 been operating since 2007.
46
47
48
49

50 Identified reports of myocarditis and myopericarditis in 12–17-year-old vaccinees submitted
51
52 to SAEFVIC between 22 February and 22 February 2022 were assessed. The majority of
53
54 these were practitioner reported. Myocarditis and myopericarditis reports (henceforth
55
56 summarized as myocarditis) were systematically followed up and diagnostic test results
57
58
59
60

1
2
3 (where available) obtained to confirm the diagnoses, including potential alternative causes
4 such as viral, autoimmune or medication related myocarditis. Data gathered included a list
5
6 such as viral, autoimmune or medication related myocarditis. Data gathered included a list
7
8 of symptoms such as chest pain, shortness of breath, dizziness and fatigue (Table 1), as well
9
10 as investigations undertaken by treating clinicians, including electrocardiogram (ECG),
11
12 cardiac biomarkers, echocardiogram and cardiac magnetic resonance imaging (MRI) scans.
13
14 All troponin levels obtained were high sensitivity troponin assays, with troponin levels
15
16 reported as fold increase from the upper limit of normal to facilitate comparison between
17
18 different assays.
19
20
21
22
23

24 Once data were available, each case was categorized by at least two independent experts
25
26 utilizing the Brighton Collaboration definition with graded levels of certainty (Table 1). (11)
27
28 All reports were forwarded to the national regulator, the Therapeutic Goods Administration
29
30 (TGA), who report weekly on spontaneous AEFI reports at a national level. (12, 13)
31
32
33

34 Cases where vaccination was the most likely cause of their diagnosis were followed up after
35
36 one month to answer a series of questions about ongoing symptoms and clinical
37
38 management. Cases were declared lost to follow up after three unsuccessful attempts to
39
40 contact.
41
42
43
44

45 **Statistical analysis**

46
47 Data were analysed using Microsoft PowerBI (version 2.91.701.0) with 90% Poisson
48
49 confidence intervals calculated for rates. Vaccine doses administered and population
50
51 estimates were obtained from the Australian Immunisation Registry (AIR). (14) Age groups
52
53 were defined by the vaccine roll-out in Victoria, whereby 16–17-year-olds were eligible for
54
55
56
57
58
59
60

1
2
3 vaccination prior to 12–15-year-olds. Mood's median test was used to compare median fold
4
5 increase in troponin levels.
6
7
8
9

10 **RESULTS**

11
12 As of 22 February 2022, 454,974 12–17-year-old Victorians had received 871,689 mRNA
13
14 doses (782,964 Comirnaty and 88,725 Spikevax). This equated to approximately 97.9% first
15
16 dose and 93.7% 2nd dose coverage of this age cohort.
17
18
19

20
21 At this timepoint, there were 75 reports of confirmed myocarditis (44 myocarditis, 31
22
23 myopericarditis) as per Brighton Collaboration level 1 (definitive) or 2 (probable) criteria.
24
25 This equates to a rate of 8.3 per 100,000 doses (90% CI: 6.8, 10.1) in this age group (Table
26
27 1).
28
29

30
31 Cases were predominantly in males (n=62, 82.7%) and post dose 2 (n=61, 81.3%).
32
33

34
35 Presentation was temporally related to Comirnaty in 63 (84.10) and to Spikevax in 12
36
37 (16.0%) cases respectively. Higher rates were observed in the 16–17-year-old age group,
38
39 and in males compared to females ($p<0.001$) (Table 2).
40
41

42
43 Of the 75 cases in the study period, 5 of them were considered by the treating clinician to
44
45 have an alternative cause for myocarditis more likely than COVID-19 vaccination. One of
46
47 these cases had evidence of historical COVID-19 infection, with a positive COVID-19
48
49 respiratory PCR three weeks prior to receiving first dose Comirnaty vaccination – with
50
51 subsequent onset of myocarditis two days later.
52
53
54

55
56 For the 70 cases related to COVID-19 mRNA vaccination, onset of symptoms ranged from 0
57
58 to 49 days after vaccination, with a median of 2 days (IQR 1-3 days), in males from 0 to 34
59
60

1
2
3 days (median 2 days) and in females 1 to 49 days (median 2 days). Fifty-one cases (68.0%)
4
5 required hospital admission with a median length of stay of two nights. No cases required
6
7 ICU admission and no deaths were recorded. All admissions were discharged to home.
8
9

10
11 ECG abnormalities were observed in 51 (68.0%) cases. An echocardiogram was performed in
12
13 70 cases and was abnormal in 8 (11.4%). An initial diagnostic cardiac MRI was performed in
14
15 35 cases with abnormalities documented in the majority of these (31 cases, 88.6%).
16
17
18

19
20 There was a differential in troponin levels between sexes, with males exhibiting higher and
21
22 more variable increases in troponin and a median fold rise of 144 times above normal levels
23
24 compared to females at 33 times above normal ($p=0.222$) (Figure 1).
25
26
27

28
29 Follow up at one month was completed for 64 of the 70 cases where COVID-19 vaccination
30
31 was the most likely cause of their diagnosis (Table 3). The remaining 6 cases were lost to
32
33 follow-up and excluded from analysis. Symptoms had resolved in 50.0% of those who
34
35 participated in follow-up, while 64.1% remained on exercise restrictions.
36
37
38

39 **DISCUSSION**

40
41
42 We describe 75 cases of myocarditis reported following COVID-19 mRNA vaccination in the
43
44 adolescent age group. Our rate of cases was similar to other international studies in Israel,
45
46 the UK and the USA. (13)
47
48
49

50
51 This analysis describes one of the largest series of adolescents with myocarditis post-COVID-
52
53 19 mRNA vaccination to date. Rigorous clinical review demonstrated Brighton criteria
54
55 defined 'definitive' or 'probable' diagnoses for all cases. By utilising this international
56
57 standardised approach to evaluating this AESI, it allows a more accurate evaluation of
58
59
60

1
2
3 clinical features and comparison with other presentations of non-COVID-19 mRNA vaccine
4
5 myocarditis or chest pain in this age group.
6
7

8
9 Clinical findings were similar to other international cohorts of adolescents. Dionne *et al*
10
11 described similar symptom prevalence in a cohort of myocarditis patients <19 years. (15)
12
13 There was also similar cardiac MRI abnormalities noted in similar cohorts. (16) In contrast to
14
15 our findings, the cohort from Truong *et al* had a high number of patients (18.7%) requiring
16
17 ICU admission, although only 2 required inotropic support. (17) It is likely that the difference
18
19 in ICU admission criteria, rather than true clinical severity accounts for this discrepancy.
20
21
22

23
24 Unique to this study is the clear clinical phenotypic differences identified between sexes.

25
26 Males tended to present with symptoms and a significantly elevated peak troponin level.

27
28 Just under half had no residual symptoms 4 weeks after initial onset. In contrast, females
29
30 had a much lower median peak troponin level, with similar rates post dose 1 and 2.
31
32

33
34 Symptoms were still experienced by a majority of females 4 weeks after onset. These
35
36 differences may support a potential impact of testosterone as a risk factor for stronger
37
38 cardiac inflammation in myocarditis, but with a potentially beneficial impact on duration of
39
40 symptoms. (18)
41
42
43
44

45
46 Our data indicates a higher rate of cases between the age of 16-17 years and a tapering in
47
48 rate for the 12-15 year-old age group. Further analysis is needed and ongoing to compare
49
50 rates of myocarditis between Comirnaty and Spikevax when sufficient doses are
51
52 administered, although there is currently no discernible difference in case severity or clinical
53
54 presentation.
55
56
57
58
59
60

1
2
3 These observations suggest that any potential immunisation policy and vaccine safety
4 surveillance adjustments may need to take into account these age and gender differentials.
5
6 For example, it has implications for younger age groups, including those between 5-11
7
8 years, where a reduced dose (10 mcg) Comirnaty vaccine was FDA approved and Advisory
9
10 Committee on Immunization Practices (ACIP) recommended in early November 2021. (19)
11
12
13
14
15
16
17

18 No COVID-19 vaccine clinical trials to date have been sufficiently powered to detect an AESI
19
20 such as myocarditis. However, with millions of doses administered worldwide in this age
21
22 group at time of writing, real-world phase IV data will help inform the important risk-benefit
23
24 discussion regarding COVID-19 vaccines in younger children, who from background rates of
25
26 myocarditis (all causes) would be expected to have fewer cases than adolescents.
27
28
29
30
31

32 **LIMITATIONS**

34 This study is based on clinical data compiled by SAEFVIC as part of vaccine safety
35
36 surveillance. A passive vaccine safety surveillance system may underreport potential cases
37
38 of myocarditis. Furthermore, there was lack of clinical data on some cases (eg.
39
40 investigations not performed), making evaluation and diagnosis more challenging. While
41
42 patient-reported symptoms were included as part of the evaluation, Brighton diagnostic
43
44 criteria were used as a benchmark to reduce recall bias. The accuracy of diagnosis was also
45
46 maintained by ensuring that available patient clinical information were reviewed by at least
47
48 two independent medical specialists to verify reported myocarditis cases and reduce
49
50 misclassification.
51
52
53
54
55
56
57
58
59
60

CONCLUSION

Rates of myocarditis in the adolescent population differ by dose and sex in the 12 to 17-year-old age group. With the vaccine rollout in younger children and adolescents in mind, these clinical phenotypic differences should be considered for future COVID vaccine recommendations including 'booster' doses.

Acknowledgements:

SAEFVIC

Greta Goldsmith, Samar Hikmat, Josh Osowicki, Linny Phuong, Mel Addison, Louise Dempsey, Adele Harris, Georgie Lewis, Bianca Penak, Laura Voss, Jaimee Craft, Victoria Scott, Lois Tham

Department of Health (Victoria)

Anna Power, Ngaree Blow, Elise Virah Sawmy, Eleanor Duckworth, Michelle Wolthuizen, Naveen Tenneti, Nick White, Melodie Heland, Sally Gordon

VicSIS paediatric clinic sites

Jane Standish (Barwon Health), Kathleen McCloskey (Barwon Health), Brooke Doherty (Barwon Health), Catie Fleming (Austin Health), Jeremy Carr (Monash Health), Matthew O'Brien (Monash Health), Paxton Loke (Monash Health), Ciara Earley (Monash Health), David Tran (Northern Health), Shane O'Dea (Northern Health), Lianne Cox (Western Health), Yoko Asakawa (Western Health), Teresa Lazzaro (RCH), Kirsten Perrett (RCH), Shidan Tosif

1
2
3 (RCH), Wonie Uahwatanasakul (RCH) and all other medical, nursing and administrative staff
4
5 that support the VicSIS clinics.
6
7
8
9

10 All other hospital sites and clinicians involved in providing information on cases.
11
12
13

14 15 **Footnotes**

16
17 Contributors: DC, NC, JB conceived and designed the study. HC, ER and HM performed
18
19 statistical analyses and data management. All authors were involved in drafting, editing and
20
21 reviewing the article. All corresponding authors meet the authorship criteria. DC is the
22
23 study's guarantor.
24
25
26
27

28
29
30 Funding: This study was unfunded and was part of a routine clinical surveillance program.
31
32
33

34
35 Competing interests: All authors have completed the Unified Competing Interest
36
37 form (available on request from the corresponding author) and declare: no support from
38
39 any organisation for the submitted work; no financial relationships with any organisations
40
41 that might have an interest in the submitted work in the previous three years, no other
42
43 relationships or activities that could appear to have influenced the submitted work.
44
45
46
47

48
49 Ethics approval: Follow-up of cases was undertaken as part of public health AEFI
50
51 management. SAEFVIC data is part of a clinical quality registry that forms part of Victoria's
52
53 vaccine safety surveillance program.
54
55
56
57
58
59
60

1
2
3 Data sharing: Aggregated de-identified and summarized data are publicly available at
4
5 <https://mvec.mcri.edu.au/vaccinesafety/>
6
7
8
9

10 Patient Involvement: Patients were not involved in the report and conduct of this research,
11
12 as data were collected as part of public health AEFI management and was not a specific
13
14 research trial.
15
16
17
18
19

20 Transparency Declaration: The lead author, Dr Daryl Cheng, affirms that the manuscript is an
21
22 honest, accurate, and transparent account of the study being reported; that no important
23
24 aspects of the study have been omitted; and that any discrepancies from the study as
25
26 planned have been explained.
27
28
29
30
31

32 The Corresponding Author has the right to grant on behalf of all authors and does grant on
33
34 behalf of all authors, an exclusive licence (or non exclusive for government employees) on a
35
36 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
37
38 published in BMJ editions and any other BMJ PGL products and sublicences such use and
39
40 exploit all subsidiary rights, as set out in our licence.
41
42
43
44
45
46
47
48
49
50
51

52 References

- 54 1. Operation COVID Shield. National COVID Vaccine Campaign Plan. 2021. Available at:
55 [https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-](https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-national-covid-vaccine-campaign-plan.pdf)
56 [national-covid-vaccine-campaign-plan.pdf](https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-national-covid-vaccine-campaign-plan.pdf)
57
- 58 2. Ministry of Health, Government of Israel. Surveillance of Myocarditis (Inflammation of the
59 Heart Muscle) Cases Between December 2020 and May 2021. 2021. Available online:
60 <https://www.gov.il/en/departments/news/01062021-03>

3. Barda N, Dagan N, Ben-Shlomo Y, *et al.* Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med.* 2021; doi: 10.1056/nejmoa2110475
4. Montgomery J, Ryan M, Engler R, *et al.* Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol.* 2021;**6**:1202 doi: 10.1001/jamacardio.2021.2833 [published Online].
5. Kim HW, Jenista ER, Wendell DC, *et al.* Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol.* 2021; doi: 10.1001/jamacardio.2021.2828 [published Online First: 2021/06/30].
6. Patone M, Mei XW, Handunnetthi L, *et al.* Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nature Med.* 2021; doi: 10.1038/s41591-021-01630-0
7. Centers for Disease Control and Prevention (CDC). ACIP Presentation Slides: November 2-3, 2021 Meeting. 2021. Available online: <https://www.cdc.gov/vaccines/acip/meetings/slides-2021-11-2-3.html>
8. Gellad WF. Myocarditis after vaccination against covid-19. *BMJ.* 2021;**375**:n3090 doi: 10.1136/bmj.n3090.
9. Australian Bureau of Statistics. National, state and territory population. 2020. Available online: <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release>
10. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. *Commun Dis Intell Q Rep.* 2011;**35**:294-8.
11. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, *et al.* Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine.* 2022; doi: 10.1016/j.vaccine.2021.11.074 [published online: 2022/01/31].
12. Therapeutic Goods Administration (TGA). Reporting suspected side effects associated with a COVID-19 vaccine. 2021; Available online: <https://www.tga.gov.au/reporting-suspected-side-effects-associated-covid-19-vaccine>.
13. Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report - 14.04.2022. 2022. Available online: <https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report>
14. Services Australia. Australian Immunisation Register. Australian Government 2021. Available online: <https://www.servicesaustralia.gov.au/australian-immunisation-register>
15. Dionne A, Sperotto F, Chamberlain S, *et al.* Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiol.* 2021;**6**:1446-50 doi: 10.1001/jamacardio.2021.3471 [published Online First: 2021/08/11].
16. Jain SS, Steele JM, Fonseca B, *et al.* COVID-19 Vaccination-Associated Myocarditis in Adolescents. *Pediatrics.* 2021;**148** doi: 10.1542/peds.2021-053427 [published Online First: 2021/08/15].
17. Truong DT, Dionne A, Muniz JC, *et al.* Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination. *Circulation.* 2022;**145**:345-56 doi: 10.1161/circulationaha.121.056583 [published Online First: 2021/12/07].
18. Barcena ML, Jeuthe S, Niehues MH, *et al.* Sex-Specific Differences of the Inflammatory State in Experimental Autoimmune Myocarditis. *Frontiers in Immunology.* 2021;**12** doi: 10.3389/fimmu.2021.686384
19. Centers for Disease Control and Prevention (CDC). COVID Data Tracker. 2021. Available online: <https://covid.cdc.gov/covid-data-tracker/>

Figure 1: Peak troponin differential between male and females

Table 1: Brighton Collaboration Criteria for Myocarditis

Level 1 – “Definitive” Case	Level 2 – “Probable Case”	Level 3 – “Possible Case”
<p>Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation</p> <p>OR</p> <p>≥ 1 new finding of</p> <ul style="list-style-type: none"> • Troponin T or I level above upper limit of normal <p>AND</p> <p>≥ 1 new Cardiac MRI (cMRI) findings consistent with</p> <ul style="list-style-type: none"> • Oedema on T2 weighted study, typically patchy in nature • Late gadolinium enhancement on T1 weighted study with an increased enhancement ratio between myocardial and skeletal muscle typically involving at least one non- 	<p>Clinical symptoms and exclusion as per Level 3 case</p> <p>AND</p> <p>Elevated myocardial biomarkers ≥ 1 new finding of</p> <ul style="list-style-type: none"> • Troponin T level above upper limit of normal • Troponin I level above upper limit of normal • CK Myocardial band <p>OR</p> <p>Echocardiogram (ECHO) abnormalities ≥ 1 new finding of</p> <ul style="list-style-type: none"> • focal or diffuse left or right ventricular function abnormalities (eg. decreased ejection fraction) • Segmental wall motion abnormalities 	<p>Presence of ≥ 1 new or worsening of the following clinical symptoms:</p> <ul style="list-style-type: none"> • chest pain/pressure • dyspnoea /shortness of breath/pain breathing • diaphoresis • palpitations • Sudden Death <p>OR</p> <p>Presence of ≥ 2 new or worsening of the following clinical symptoms:</p> <ul style="list-style-type: none"> • Fatigue • Abdominal Pain • Syncope • Oedema • Cough <p>AND</p>

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>ischemic regional distribution with recovery (myocyte injury).</p> <p>OR</p> <p>Echocardiogram (ECHO) abnormalities biomarkers ≥ 1 new finding of as per level 2 case</p>	<ul style="list-style-type: none"> • Global systolic or diastolic function depression/abnormality • Ventricular dilation • Wall thickness change • Intracavitary thrombi <p>OR</p> <p>Electrocardiogram (ECG) abnormalities ≥ 1 new finding of</p> <ul style="list-style-type: none"> • Paroxysmal or sustained atrial or ventricular arrhythmias (premature atrial or ventricular beats, and/or supraventricular or ventricular tachycardia, interventricular conduction delay, abnormal Q waves, low voltages) • AV nodal conduction delays or intraventricular conduction defects (atrioventricular block (grade I-III), new bundle branch block) • Continuous ambulatory electrocardiographic monitoring that detects frequent atrial or ventricular ectopy 	<p>≥ 1 new supported finding of inflammation</p> <p>Elevated CRP/ESR or D-Dimer</p> <p>AND</p> <p>Presence of ≥ 1 new abnormal electrocardiogram (ECG) such as:</p> <ul style="list-style-type: none"> • ST-segment or T-wave abnormalities (elevation or inversion) • PACs and PVCs <p>AND</p> <ul style="list-style-type: none"> • no other identifiable cause of the symptoms and findings
--	--	--


Table 2: Count and rate of cases by sex, age group, dose number, and Brighton Collaboration level

		Male		Female		Total	
		Count	Rate per 100,000 doses (90% CI)	Count	Rate per 100,000 doses (90% CI)	Count	Rate per 100,000 doses (90% CI)
Total		62	13.6 (10.9, 16.8)	13	2.9 (1.7, 4.7)	75	8.3 (6.8, 10.1)
Age group (years)	12-15	34	11.4 (8.4, 15.2)	7	2.4 (1.1, 4.6)	41	7.0 (5.3, 9.1)
	16-17	28	17.7 (12.6, 24.2)	6	3.9 (1.7, 7.6)	34	10.8 (8.0, 14.4)
Dose	1	10	4.4 (2.4, 7.5)	4	1.8 (0.6, 4.2)	14	3.2 (1.9, 4.9)
	2	52	24.2 (19.0, 30.5)	9	4.3 (2.3, 7.5)	61	14.4 (11.5, 17.8)
Brighton Collaboration level	Definitive	27	5.9 (4.2, 8.2)	3	0.7 (0.2, 1.8)	30	3.3 (2.4, 4.5)
	Probable	35	7.7 (5.7, 10.2)	10	2.3 (1.2, 3.8)	45	5.0 (3.8, 6.4)

Table 3: One-month follow up outcomes, by sex (n=64)

	Male (n=56)	Female (n=8)	Total (n=64)	Chi-square statistic (p-value)
	Count, %	Count, %	Count, %	
Symptoms resolved	31, 55.4%	1, 12.5%	32, 50.0%	5.14 (p=0.02)
On exercise restrictions	35, 62.5%	6, 75.0%	41, 64.1%	0.48 (p=0.49)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



327x93mm (96 x 96 DPI)

BMJ Paediatrics Open

Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12–17-year-olds in Victoria, Australia

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001472.R3
Article Type:	Original research
Date Submitted by the Author:	30-May-2022
Complete List of Authors:	Cheng, Daryl; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Clothier, Hazel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Campus, Centre for Health Analytics Morgan, Hannah; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Campus, Centre for Health Analytics Roney, Emma; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; Melbourne Children's Centre, Centre for Health Analytics Shenton, Priya; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Cox, Nicholas; Western Health, Department of Cardiology Jones, Bryn; The Royal Children's Hospital Melbourne, Department of Cardiology Schrader, Silja; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity Crawford, Nigel; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne Buttery, Jim; Murdoch Children's Research Institute, SAEFVIC, Infection and Immunity; The Royal Children's Hospital Melbourne
Keywords:	COVID-19, Cardiology, Adolescent Health

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to**
4
5
6 **12–17 year-olds in Victoria, Australia**
7

8 **Authors:** Daryl R Cheng (0000-0001-5455-957X), Immunisation Consultant, SAEFVIC ^{1,2,3,4*},
9 Hazel J Clothier (0000-0001-7594-0361), Principal epidemiologist and Surveillance Manager,
10 SAEFVIC ^{1,4,5*}, Priya Shenton, immunisation fellow, SAEFVIC ¹, Emma Roney, Senior
11 epidemiologist, SAEFVIC ^{1,4}, Hannah Morgan (0000-0001-8717-908X), Senior epidemiologist,
12 SAEFVIC ^{1,3,4}, Nicholas Cox (0000-0001-7442-2829), Director of Cardiology, Western Health ⁶,
13 Bryn Jones, Deputy Director of Cardiology, Royal Children's Hospital ^{2,3}, Silja Schrader (0000-
14 0003-1776-6152), data officer, SAEFVIC ¹, Nigel W Crawford (0000-0003-1851-5080), Director,
15 SAEFVIC ^{1,2,3} ** and Jim P Buttery, Professor Child Health Informatics ^{1,2,3,4,**}, on behalf of the
16 SAEFVIC and VicSIS investigators
17
18
19

20 * Joint 1st authors

21 ** Joint senior authors
22
23

24 **Affiliations:**

25 ¹SAEFVIC, Infection and Immunity, Murdoch Children's Research Institute, Melbourne,
26 Australia

27 ² The Royal Children's Hospital, Melbourne, Australia

28 ³ Department of Paediatrics, University of Melbourne, Melbourne, Australia,

29 ⁴ Centre for Health Analytics, Melbourne Children's Campus, Australia

30 ⁵ Melbourne School of Population and Global Health, University of Melbourne, Parkville,
31 Australia

32 ⁶ Department of Cardiology, Western Health, Sunshine, Australia
33
34
35

36 **Corresponding Author**

37 Daryl Cheng

38 SAEFVIC

39 50 Flemington Rd

40 Parkville

41 VIC 3052

42 E: daryl.cheng@mcri.edu.au
43
44
45

46 **Word Count:** 1902
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT**Importance:**

COVID-19 mRNA vaccine associated myocarditis has previously been described; however specific features in the adolescent population are currently not well understood.

Objective

To describe myocarditis adverse events following immunization (AEFI) reported following any COVID-19 mRNA vaccines in the adolescent population in Victoria, Australia.

Design

Statewide, population-based study.

Setting

Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) is the vaccine-safety service for Victoria, Australia.

Participants

All SAEFVIC reports of myocarditis and myopericarditis in 12–17-year-old COVID-19 mRNA vaccinees submitted between 22 February 2021 and 22 February 2022, as well as accompanying diagnostic investigation results where available, were assessed using Brighton Collaboration criteria for diagnostic certainty.

Exposures

Any mRNA COVID-19 vaccine

Main Outcomes/Measure

Confirmed myocarditis as per Brighton Collaboration criteria (levels 1-3)

Results

Clinical review demonstrated definitive (Brighton level 1) or probable (level 2) diagnoses in 75 cases. Confirmed myocarditis reporting rates were 8.3 per 100,000 doses in this age group. Cases were predominantly male (n=62, 82.7%) and post dose 2 (n=61, 81.3%). Rates peaked in the 16–17year-old age group and were higher in males than females (17.7 v 3.9 per 100,000, $p<0.001$).

The most common presenting symptoms were chest pain, dyspnoea and palpitations. A large majority of cases who had a cardiac MRI had abnormalities (n=33, 91.7%). Females were more likely to have ongoing clinical symptoms at 1 month follow-up ($p=0.02$).

Conclusion

Accurate evaluation and confirmation of episodes of COVID-19 mRNA vaccine associated myocarditis enabled understanding of clinical phenotypes in the adolescent age group. Any potential vaccination and safety surveillance policies needs to consider age and gender differences.

What is already known on this topic

- Previous case studies suggest that there is an association between COVID-19 mRNA vaccines and increased rates of myocarditis, most commonly in the following 2 weeks
- Recommendations on use of COVID-19 mRNA vaccines in different age groups vary globally and may not take into account their different risk profiles.

What this study adds

- Incidence of myocarditis post COVID-19 mRNA vaccines are higher after the second dose and appears to differ by age and gender, with adolescent and young adult males being at a higher risk.
- Females were more likely to have ongoing clinical symptoms at one month followup compared to males

How this study might affect research, practice or policy

- Potential policy and safety surveillance adjustments may need to take into account age and gender differentials in myocarditis when reviewing COVID-19 primary (2-dose) vaccine rollout to the adolescent population

INTRODUCTION

Australia has utilized two mRNA vaccines as part of its COVID-19 vaccine strategy in 12-17 year-olds, namely Comirnaty® BNT162b2 COVID-19 (Pfizer-BioNTech) and Spikevax® mRNA-1273 (Moderna). (1) Comirnaty was initially provisionally licensed by the Australian regulator, the Therapeutic Goods Administration (TGA) for those aged 16 years and older, and administered from 25 January 2021 in adults 18+ years. Spikevax received provisional TGA approval for administration in individuals from 18 years from 9 August 2021. Following the availability of age specific clinical trial data, further approvals were added for the 12–15-year-old group for Comirnaty (22nd July 2021) and 12–17-year-old for Spikevax (4th September 2021).

Of particular interest in the young adult population is post-vaccination myocarditis and pericarditis causally associated with COVID-19 mRNA vaccines. These adverse events of special interest (AESI) were first flagged in Israel, which implemented Comirnaty at a population level as soon as it was available (20th December 2020). (2) In a linked electronic health record observational case control study design from Israel's largest health care insurer, Barda *et al* described an elevated risk of myocarditis following Comirnaty (risk ratio [RR], 3.24; 95% confidence interval [CI], 1.55 to 12.44) , while noting a substantially higher risk following COVID-19 disease (RR 18.28; 95% CI, 3.95 to 25.12). (3)

Subsequent post-licensure observational military and report-based case studies confirmed the highest risk group for post mRNA COVID-19 vaccine myocarditis is young males (<24 years old) following the 2nd vaccine dose. (4-6) Both the spontaneous Vaccine Adverse Event Reporting System and active Vaccine Safety Datalink surveillance systems in the US have

1
2
3 confirmed a myocarditis signal safety (7), along with similar findings in Canada, the UK and
4
5 various Nordic countries. (6)
6
7
8
9

10 The case phenotype includes chest pain as the most common symptom, but also includes
11
12 fever, shortness of breath and other non-specific symptoms such as headache, myalgia and
13
14 vomiting. Common investigation findings include a raised troponin, abnormal
15
16 electrocardiogram (ECG) with ST or T wave changes, and late gadolinium enhancement or
17
18 myocardial oedema seen on cardiac magnetic resonance imaging (MRI). (8-11)
19
20
21
22
23
24

25 Due to this AESI signal, the risk, clinical manifestations and follow-up of myocarditis and
26
27 pericarditis following mRNA COVID-19 in younger populations has been of particular
28
29 interest. Some regions (e.g., Hong Kong) are only administering a single dose of mRNA
30
31 vaccine in adolescents aged 12-17 years and notably, there is limited use of Spikevax in this
32
33 age group internationally. Spikevax is not currently licensed by the US Food and Drug
34
35 Administration (FDA) for 12-17 year-olds, whilst Canada and several European countries
36
37 have issued preferential recommendations for Comirnaty over Spikevax for young adults.
38
39
40 (12) This study describes clinical presentation and evaluation of myocarditis AESI following
41
42 mRNA COVID-19 vaccination in 12–17-year-old adolescents in Victoria, Australia.
43
44
45
46
47
48
49

50 **METHODS**

51 Victoria is a south-eastern Australian state with a population of approximately 6.6 million.
52
53

54 (13) AEFI are spontaneously reported by patients, caregivers or health-care providers to
55
56 SAEFVIC, the state-wide vaccine safety service. (14) SAEFVIC comprises central reporting
57
58
59
60

1
2
3 enhanced passive and active surveillance systems integrated with clinical services and has
4
5 been operating since 2007.
6
7

8
9 Identified reports of myocarditis and myopericarditis in 12–17-year-old vaccinees submitted
10
11 to SAEFVIC between 22 February 2021 and 22 February 2022 were assessed. The majority of
12
13 these were practitioner reported. Myocarditis and myopericarditis reports (henceforth
14
15 summarized as myocarditis) were systematically followed up and diagnostic test results
16
17 (where available) obtained to confirm the diagnoses, including potential alternative causes
18
19 such as viral, autoimmune or medication related myocarditis. Data gathered included a list
20
21 of symptoms such as chest pain, shortness of breath, dizziness and fatigue (Table 1), as well
22
23 as investigations undertaken by treating clinicians, including ECG, cardiac biomarkers,
24
25 echocardiogram and cardiac MRI scans. All troponin levels obtained were high sensitivity
26
27 troponin assays, with troponin levels reported as fold increase from the upper limit of
28
29 normal to facilitate comparison between different assays.
30
31
32
33
34
35
36

37 Once data were available, each case was categorized by at least two independent experts
38
39 utilizing the Brighton Collaboration definition with graded levels of certainty (Table 1). (15)
40
41 All reports were forwarded to the national regulator, the Therapeutic Goods Administration
42
43 (TGA), who report weekly on spontaneous AEFI reports at a national level. (16, 17)
44
45
46
47

48 Cases where vaccination was the most likely cause of their diagnosis were followed up after
49
50 one month to answer a series of questions about ongoing symptoms and clinical
51
52 management. Cases were declared lost to follow up after three unsuccessful attempts to
53
54 contact.
55
56
57
58
59
60

Statistical analysis

Data were analysed using Microsoft PowerBI (version 2.91.701.0) with 90% Poisson confidence intervals calculated for rates. Vaccine doses administered and population estimates were obtained from the Australian Immunisation Registry (AIR). (18) Age groups were defined by the vaccine roll-out in Victoria, whereby 16–17-year-olds were eligible for vaccination prior to 12–15-year-olds. Mood's median test was used to compare median fold increase in troponin levels.

RESULTS

As of 22 February 2022, 454,974 12–17-year-old Victorians had received 871,689 mRNA doses (782,964 Comirnaty and 88,725 Spikevax). This equated to approximately 97.9% first dose and 93.7% 2nd dose coverage of this age cohort.

At this timepoint, there were 75 reports of confirmed myocarditis (44 myocarditis, 31 myopericarditis) as per Brighton Collaboration level 1 (definitive) or 2 (probable) criteria. This equates to a rate of 8.3 per 100,000 doses (90% CI: 6.8, 10.1) in this age group (Table 1).

Cases were predominantly in males (n=62, 82.7%) and post dose 2 (n=61, 81.3%).

Presentation was temporally related to Comirnaty in 63 (84.10) and to Spikevax in 12 (16.0%) cases respectively. Higher rates were observed in the 16–17-year-old age group, and in males compared to females ($p < 0.001$) (Table 2).

Of the 75 cases in the study period, 5 of them were considered by the treating clinician to have an alternative cause for myocarditis more likely than COVID-19 vaccination. One of

1
2
3 these cases had evidence of historical COVID-19 infection, with a positive COVID-19
4
5 respiratory PCR three weeks prior to receiving first dose Comirnaty vaccination – with
6
7 subsequent onset of myocarditis two days later.
8
9

10
11 For the 70 cases related to COVID-19 mRNA vaccination, onset of symptoms ranged from 0
12
13 to 49 days after vaccination, with a median of 2 days (IQR 1-3 days), in males from 0 to 34
14
15 days (median 2 days) and in females 1 to 49 days (median 2 days). Fifty-one cases (77.1%)
16
17 required hospital admission with a median length of stay of two nights. No cases required
18
19 ICU admission and no deaths were recorded. All admissions were discharged to home.
20
21
22

23
24 All cases had chest pain as a presenting symptom. Other common symptoms included
25
26 dyspnoea (21 cases, 30%), palpitations (14,20%) and diaphoresis. 33 cases (47.1%) had
27
28 concomitant non-specific symptoms such as dizziness, vomiting and fatigue (Table 3).
29
30
31

32
33 ECG abnormalities were observed in 49 (70.0%) cases, with the most common finding being
34
35 ST-elevation. An echocardiogram was performed in 70 cases and was abnormal in 8 (11.4%).
36
37

38
39 An initial diagnostic cardiac MRI was performed in 36 cases with abnormalities documented
40
41 in the majority of these (33 cases, 91.7%) (Table 3).
42
43

44
45 There was a trend for males toward higher and more variable increases in troponin, with a
46
47 median fold rise of 144 times above normal levels compared to females at 33 times above
48
49 normal ($p=0.222$) (Figure 1).
50
51

52
53 Follow up at one month was completed for 64 of the 70 cases where COVID-19 vaccination
54
55 was the most likely cause of their diagnosis (Table 4). The remaining 6 cases were lost to
56
57 follow-up and excluded from analysis. Symptoms remained in 50.0% of those who
58
59
60

1
2
3 participated in follow-up, with a higher percentage of females having ongoing symptoms
4
5 (44.6 vs 87.5%, $p=0.02$) including chest pain (48.0 vs 71.4%, $p=0.01$) (Table 4).
6
7

8 9 DISCUSSION

10
11
12 We describe 75 cases of myocarditis reported following COVID-19 mRNA vaccination in the
13
14 adolescent age group. Our rate of cases was similar, albeit slightly higher than other
15
16 international studies in Israel, the UK and the USA. (17)
17
18

19
20
21 This rate likely reflects concerted public health messaging and awareness of the AESI,
22
23 coupled with the combination of active and passive surveillance methodology to ascertain
24
25 these cases. Whilst this may have led to increased reporting rates, the robust diagnostic
26
27 criteria requiring laboratory and imaging tests to confirm myocarditis, together with tight
28
29 COVID-19 related environmental restrictions that significantly reduced the chance of COVID-
30
31 19 infection related myocarditis, indicate that this is likely to represent an accurate rate.
32
33
34

35
36
37 Clinical findings were also similar to other international cohorts of adolescents. Dionne *et al*
38
39 described similar symptom prevalence in a cohort of myocarditis patients <19 years. (19)

40
41
42 There was also similar cardiac MRI abnormalities noted in similar cohorts. (20) In contrast to
43
44 our findings, the cohort from Truong *et al* had a high number of patients (18.7%) requiring
45
46 ICU admission, although only 2 required inotropic support. (8) It is likely that the difference
47
48 in ICU admission criteria, rather than true clinical severity accounts for this discrepancy.
49
50
51

52
53 Unique to this study is the clear clinical phenotypic differences identified between sexes.

54
55 Males tended to present with symptoms and a significantly elevated peak troponin level.

56
57 Just under half had no residual symptoms 4 weeks after initial onset. In contrast, females
58
59
60

1
2
3 tended to have had a much lower median peak troponin level, with similar rates post dose 1
4
5 and 2. Symptoms were still experienced by a majority of females 4 weeks after onset. These
6
7 differences may support a potential impact of testosterone as a risk factor for stronger
8
9 cardiac inflammation in myocarditis, but with a potentially beneficial impact on duration of
10
11 symptoms. (21)
12
13
14
15

16 Our data indicates a higher rate of cases between the age of 16-17 years and a tapering in
17
18 rate for the 12-15 year-old age group. Further analysis is needed and ongoing to compare
19
20 rates of myocarditis between Comirnaty and Spikevax when sufficient doses are
21
22 administered, although there is currently no discernible difference in case severity or clinical
23
24 presentation.
25
26
27
28

29 These observations suggest that any potential immunisation policy and vaccine safety
30
31 surveillance adjustments may need to take into account these age and gender differentials.
32
33 For example, it has implications for younger age groups, including those between 5-11
34
35 years, where a reduced dose (10 mcg) Comirnaty vaccine was FDA approved and Advisory
36
37 Committee on Immunization Practices (ACIP) recommended in early November 2021. (22)
38
39
40
41
42
43

44 No COVID-19 vaccine clinical trials to date have been sufficiently powered to detect an AESI
45
46 such as myocarditis. However, with millions of doses administered worldwide in this age
47
48 group at time of writing, real-world phase IV data will help inform the important risk-benefit
49
50 discussion regarding COVID-19 vaccines in younger children, who from background rates of
51
52 myocarditis (all causes) would be expected to have fewer cases than adolescents.
53
54
55
56
57
58
59
60

LIMITATIONS

This study is based on clinical data compiled by SAEFVIC as part of vaccine safety surveillance. A passive vaccine safety surveillance system may underreport potential cases of myocarditis. Furthermore, there was lack of clinical data on some cases (eg. investigations not performed), making full description of clinical phenotype, evaluation and diagnosis more challenging. While patient-reported symptoms were included as part of the evaluation, Brighton diagnostic criteria were used as a benchmark to reduce recall bias. The accuracy of diagnosis was also maintained by ensuring that available patient clinical information were reviewed by at least two independent medical specialists to verify reported myocarditis cases and reduce misclassification.

CONCLUSION

Rates of myocarditis in the adolescent population differ by dose and sex in the 12 to 17-year-old age group. With the vaccine rollout in younger children and adolescents in mind, these clinical phenotypic differences should be considered for future COVID vaccine recommendations including 'booster' doses.

Acknowledgements:**SAEFVIC**

Greta Goldsmith, Samar Hikmat, Josh Osowicki, Linny Phuong, Mel Addison, Louise Dempsey, Adele Harris, Georgie Lewis, Bianca Penak, Laura Voss, Jaimee Craft, Victoria Scott, Lois Tham

Department of Health (Victoria)

Anna Power, Ngaree Blow, Elise Virah Sawmy, Eleanor Duckworth, Michelle Wolthuizen, Naveen Tenneti, Nick White, Melodie Heland, Sally Gordon

VicSIS paediatric clinic sites

Jane Standish (Barwon Health), Kathleen McCloskey (Barwon Health), Brooke Doherty (Barwon Health), Catie Fleming (Austin Health), Jeremy Carr (Monash Health), Matthew O'Brien (Monash Health), Paxton Loke (Monash Health), Ciara Earley (Monash Health), David Tran (Northern Health), Shane O'Dea (Northern Health), Lianne Cox (Western Health), Yoko Asakawa (Western Health), Teresa Lazzaro (RCH), Kirsten Perrett (RCH), Shidan Tosif (RCH), Wonie Uahwatanasakul (RCH) and all other medical, nursing and administrative staff that support the VicSIS clinics.

All other hospital sites and clinicians involved in providing information on cases.

Footnotes

Contributors: DC, NC, JB conceived and designed the study. HC, ER and HM performed statistical analyses and data management. All authors were involved in drafting, editing and

1
2
3 reviewing the article. All corresponding authors meet the authorship criteria. DC is the
4
5 study's guarantor.
6
7
8
9

10 Funding: This study was unfunded and was part of a routine clinical surveillance program.
11
12
13

14
15 Competing interests: All authors have completed the Unified Competing Interest
16
17 form (available on request from the corresponding author) and declare: no support from
18
19 any organisation for the submitted work; no financial relationships with any organisations
20
21 that might have an interest in the submitted work in the previous three years, no other
22
23 relationships or activities that could appear to have influenced the submitted work.
24
25
26
27
28
29

30 Ethics approval: Follow-up of cases was undertaken as part of public health AEFI
31
32 management. SAEFVIC data is part of a clinical quality registry that forms part of Victoria's
33
34 vaccine safety surveillance program.
35
36
37
38
39

40 Data sharing: Aggregated de-identified and summarized data are publicly available at
41
42 <https://mvec.mcri.edu.au/vaccinesafety/>
43
44
45
46

47 Patient Involvement: Patients were not involved in the report and conduct of this research,
48
49 as data were collected as part of public health AEFI management and was not a specific
50
51 research trial.
52
53
54
55
56

57 Transparency Declaration: The lead author, Dr Daryl Cheng, affirms that the manuscript is an
58
59 honest, accurate, and transparent account of the study being reported; that no important
60

1
2
3 aspects of the study have been omitted; and that any discrepancies from the study as
4
5
6 planned have been explained.
7
8
9

10 The Corresponding Author has the right to grant on behalf of all authors and does grant on
11
12 behalf of all authors, an exclusive licence (or non exclusive for government employees) on a
13
14 worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be
15
16 published in BMJ editions and any other BMJPL products and sublicences such use and
17
18 exploit all subsidiary rights, as set out in our licence.
19
20
21
22
23
24

25 References

- 26 1. Operation COVID Shield. National COVID Vaccine Campaign Plan. 2021. Available at:
27 [https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-](https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-national-covid-vaccine-campaign-plan.pdf)
28 [national-covid-vaccine-campaign-plan.pdf](https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-national-covid-vaccine-campaign-plan.pdf)
- 29 2. Ministry of Health Government of Israel. Surveillance of Myocarditis (Inflammation
30 of the Heart Muscle) Cases Between December 2020 and May 2021. 2021. Available
31 online: <https://www.gov.il/en/departments/news/01062021-03>
- 32 3. Barda N, Dagan N, Ben-Shlomo Y, *et al.* Safety of the BNT162b2 mRNA Covid-19
33 Vaccine in a Nationwide Setting. *New England Journal of Medicine*. 2021; doi:
34 10.1056/nejmoa2110475
- 35 4. Montgomery J, Ryan M, Engler R, *et al.* Myocarditis Following Immunization With
36 mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiology*.
37 2021;6:1202 doi: 10.1001/jamacardio.2021.2833
- 38 5. Kim HW, Jenista ER, Wendell DC, *et al.* Patients With Acute Myocarditis Following
39 mRNA COVID-19 Vaccination. *JAMA Cardiol*. 2021; doi:
40 10.1001/jamacardio.2021.2828 [published Online First: 2021/06/30].
- 41 6. Patone M, Mei XW, Handunnetthi L, *et al.* Risks of myocarditis, pericarditis, and
42 cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
43 *Nature Medicine*. 2021; doi: 10.1038/s41591-021-01630-0
- 44 7. Centers for Disease Control and Prevention. ACIP Presentation Slides: November 2-3,
45 2021 Meeting. 2021. Available online:
46 <https://www.cdc.gov/vaccines/acip/meetings/slides-2021-11-2-3.html>
- 47 8. Truong DT, Dionne A, Muniz JC, *et al.* Clinically Suspected Myocarditis Temporally
48 Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected
49 Myocarditis After COVID-19 Vaccination. *Circulation*. 2022;145:345-56 doi:
50 10.1161/circulationaha.121.056583
- 51 9. Oster ME, Shay DK, Su JR, *et al.* Myocarditis Cases Reported After mRNA-Based
52 COVID-19 Vaccination in the US From December 2020 to August 2021. *Jama*.
53
54
55
56
57
58
59
60

- 2022;**327**:331-40 doi: 10.1001/jama.2021.24110 [published Online First: 2022/01/26].
10. Manfredi R, Bianco F, Bucciarelli V, *et al.* Clinical Profiles and CMR Findings of Young Adults and Pediatrics with Acute Myocarditis Following mRNA COVID-19 Vaccination: A Case Series. *Vaccines (Basel)*. 2022;**10** doi: 10.3390/vaccines10020169 [published Online First: 2022/02/27].
 11. Kildegaard H, Lund LC, Hojlund M, Stensballe LG, Pottegard A. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. *Bmj*. 2022;**377**:e068898 doi: 10.1136/bmj-2021-068898 [published Online First: 2022/04/13].
 12. Gellad WF. Myocarditis after vaccination against covid-19. *Bmj*. 2021;**375**:n3090 doi: 10.1136/bmj.n3090 Australian Bureau of Statistics. National, state and territory population. 2020. Available online: <https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release>
 13. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. *Commun Dis Intell Q Rep*. 2011;**35**:294-8 Online.
 14. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, *et al.* Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2022;**40**:1499-511 doi: 10.1016/j.vaccine.2021.11.074 [published Online First: 2022/02/03].
 15. Therapeutic Goods Administration (TGA). Reporting suspected side effects associated with a COVID-19 vaccine. 2021; Available online: <https://www.tga.gov.au/reporting-suspected-side-effects-associated-covid-19-vaccine>.
 16. Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report - 14.04.2022. 2022. Available online: <https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report>
 17. Services Australia. Australian Immunisation Register. Australian Government 2021. Available online: <https://www.servicesaustralia.gov.au/australian-immunisation-register>
 18. Dionne A, Sperotto F, Chamberlain S, *et al.* Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiol*. 2021;**6**:1446-50 doi: 10.1001/jamacardio.2021.3471 [published Online First: 2021/08/11].
 19. Jain SS, Steele JM, Fonseca B, *et al.* COVID-19 Vaccination-Associated Myocarditis in Adolescents. *Pediatrics*. 2021;**148** doi: 10.1542/peds.2021-053427 [published Online First: 2021/08/15].
 20. Barcena ML, Jeuthe S, Niehues MH, *et al.* Sex-Specific Differences of the Inflammatory State in Experimental Autoimmune Myocarditis. *Frontiers in Immunology*. 2021;**12** doi: 10.3389/fimmu.2021.686384
 21. Centers for Disease Control and Prevention. COVID Data Tracker. 2021. Available online: <https://covid.cdc.gov/covid-data-tracker/>

Figure 1: Peak troponin differential between male and females**Table 1: Brighton Collaboration Criteria for Myocarditis**

Level 1 – “Definitive” Case	Level 2 – “Probable Case”	Level 3 – “Possible Case”
<p>Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation</p> <p>OR</p> <p>≥ 1 new finding of</p> <ul style="list-style-type: none"> • Troponin T or I level above upper limit of normal <p>AND</p> <p>≥ 1 new Cardiac MRI (cMRI) findings consistent with</p> <ul style="list-style-type: none"> • Oedema on T2 weighted study, typically patchy in nature • Late gadolinium enhancement on T1 weighted study with an increased enhancement ratio between myocardial and skeletal muscle typically involving at least one non- 	<p>Clinical symptoms and exclusion as per Level 3 case</p> <p>AND</p> <p>Elevated myocardial biomarkers ≥ 1 new finding of</p> <ul style="list-style-type: none"> • Troponin T level above upper limit of normal • Troponin I level above upper limit of normal • CK Myocardial band <p>OR</p> <p>Echocardiogram (ECHO) abnormalities ≥ 1 new finding of</p> <ul style="list-style-type: none"> • focal or diffuse left or right ventricular function abnormalities (eg. decreased ejection fraction) • Segmental wall motion abnormalities 	<p>Presence of ≥ 1 new or worsening of the following clinical symptoms:</p> <ul style="list-style-type: none"> • chest pain/pressure • dyspnoea /shortness of breath/pain breathing • diaphoresis • palpitations • Sudden Death <p>OR</p> <p>Presence of ≥ 2 new or worsening of the following clinical symptoms:</p> <ul style="list-style-type: none"> • Fatigue • Abdominal Pain • Syncope • Oedema • Cough <p>AND</p>

<p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46</p> <p>ischemic regional distribution with recovery (myocyte injury).</p> <p>OR</p> <p>Echocardiogram (ECHO) abnormalities biomarkers ≥ 1 new finding of as per level 2 case</p>	<ul style="list-style-type: none"> • Global systolic or diastolic function depression/abnormality • Ventricular dilation • Wall thickness change • Intracavitary thrombi <p>OR</p> <p>Electrocardiogram (ECG) abnormalities ≥ 1 new finding of</p> <ul style="list-style-type: none"> • Paroxysmal or sustained atrial or ventricular arrhythmias (premature atrial or ventricular beats, and/or supraventricular or ventricular tachycardia, interventricular conduction delay, abnormal Q waves, low voltages) • AV nodal conduction delays or intraventricular conduction defects (atrioventricular block (grade I-III), new bundle branch block) • Continuous ambulatory electrocardiographic monitoring that detects frequent atrial or ventricular ectopy 	<p>≥ 1 new supported finding of inflammation</p> <p>Elevated CRP/ESR or D-Dimer</p> <p>AND</p> <p>Presence of ≥ 1 new abnormal electrocardiogram (ECG) such as:</p> <ul style="list-style-type: none"> • ST-segment or T-wave abnormalities (elevation or inversion) • PACs and PVCs <p>AND</p> <ul style="list-style-type: none"> • no other identifiable cause of the symptoms and findings
--	--	--

Table 2: Count and rate of cases by sex, age group, dose number, and Brighton Collaboration level

		Male		Female		Total	
		Count	Rate per 100,000 doses (90% CI)	Count	Rate per 100,000 doses (90% CI)	Count	Rate per 100,000 doses (90% CI)
Total		62	13.6 (10.9, 16.8)	13	2.9 (1.7, 4.7)	75	8.3 (6.8, 10.1)
Age group (years)	12-15	34	11.4 (8.4, 15.2)	7	2.4 (1.1, 4.6)	41	7.0 (5.3, 9.1)
	16-17	28	17.7 (12.6, 24.2)	6	3.9 (1.7, 7.6)	34	10.8 (8.0, 14.4)
Dose	1	10	4.4 (2.4, 7.5)	4	1.8 (0.6, 4.2)	14	3.2 (1.9, 4.9)
	2	52	24.2 (19.0, 30.5)	9	4.3 (2.3, 7.5)	61	14.4 (11.5, 17.8)
Brighton Collaboration level	Definitive	27	5.9 (4.2, 8.2)	3	0.7 (0.2, 1.8)	30	3.3 (2.4, 4.5)
	Probable	35	7.7 (5.7, 10.2)	10	2.3 (1.2, 3.8)	45	5.0 (3.8, 6.4)

Symptoms (N=70), n (%)	Count
Chest Pain	70 (100%)
Palpitations	14 (20.0%)
Dyspnoea	21 (30.0%)
Diaphoresis	6 (8.6%)
Non-specific symptoms (dizziness, vomiting, fatigue)	33 (47.1%)
Laboratory Test	Value
Troponin (N=70), median fold increase	138.3 (IQR 56.9-315.0)
Testing/Imaging	Count
ECG (N=70), n (%)	
Abnormal	49 (70.0%)
Normal	21 (30.0%)
Abnormal ECG findings or arrhythmias (n=49)	
ST- or T-wave changes/elevation	28 (57.1%)
ST segment depression in AVR	9 (18.4%)
PR depression without reciprocal ST depression	7 (14.3%)
AV Node conduction delay	3 (6.1%)
T wave inversion	3 (6.1%)
Other	9 (18.4%)
Echocardiogram (N=68)	
Normal function	62 (91.2%)
Abnormal function	8 (8.8%)
Systolic dysfunction	5 (62.5%)
Wall motion abnormalities	2 (25.0%)
LV strain	1 (12.5%)
Cardiac MRI (N=36)	
Abnormal findings, n (%)	33 (91.7%)
Late gadolinium enhancement	32 (97.0%)
Myocardial oedema	20 (60.6%)
Other abnormality on T2 imaging	9 (27.3%)
Pericardial effusion or inflammation	5 (15.2%)
Fibrosis	2 (2.4%)


Table 4: One-month follow up outcomes, by sex (n=64)

	Male (n=56)	Female (n=8)	Total (n=64)	Chi-square statistic (p-value)
	Count, %	Count, %	Count, %	
Ongoing symptoms	25, 44.6%	7, 87.5%	32, 50.0%	5.14 (p=0.02)
Chest pain	12, 48.0%	5, 71.4%	17, 53.1%	6.05 (p=0.01)

Fatigue	11, 44.0%	4, 57.1%	15, 46.9%	3.60 (p=0.58)
Palpitations	6, 24.0%	3, 42.8%	9, 28.1%	4.16 (p=0.41)
Dyspnoea	6, 24.0%	3, 42.8%	9, 28.1%	4.16 (p=0.41)

Confidential: For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



327x93mm (96 x 96 DPI)